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Abstract
Inhibitors of the PI3-kinase/AKT (protein kinase B) pathway are under investigation as anticancer
and antiviral agents. The benzimidazole derivative AKT inhibitor-IV (ChemBridge 5233705)
affects this pathway and exhibits potent anticancer and antiviral activity. To probe its biological
activity, we synthesized AKT inhibitor-IV and 21 analogues using a novel six-step route based on
ZrCl4-catalyzed cyclization of 1,2-arylenediamines with α,β-unsaturated aldehydes. We examined
effects on viability of HeLa carcinoma cells, viability of normal human cells (NHBE), replication
of recombinant parainfluenza virus 5 (PIV5) in HeLa cells, and replication of the intracellular
bacterium Mycobacterium fortuitum in HeLa cells. Replacement of the benzimidazole N-ethyl
substitutent of AKT inhibitor-IV with N-hexyl and N-dodecyl groups enhanced antiviral activity
and cytotoxicity against the cancer cell line, but these compounds showed substantially lower
toxicity (from 6-fold to >20-fold) against NHBE cells, and no effect on M. fortuitum, suggesting
inhibition of one or more host protein(s) required for proliferation of cancer cells and PIV5. The
key structural elements identified here may facilitate identification of targets of this highly
biologically active scaffold.
Introduction
In higher eukaryotes, the phosphatidylinositol-3-kinase (PI3K) pathway regulates a number
of critical physiological functions including vesicular trafficking, cellular growth, survival,
and proliferation. When activated, receptor tyrosine kinases, such as the epidermal growth
factor receptor, recruit PI3K to the plasma membrane, resulting in the conversion of
membrane-bound phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-
triphosphate. This lipid second messenger in turn recruits the serine-threonine kinase AKT
(also known as protein kinase B) to the plasma membrane by binding the pleckstrin
homology (PH) domain of this enzyme. At the plasma membrane, AKT is fully activated
upon phosphorylation by 3-phosphoinositide-dependent kinase (PDK1) and the rapamycin-
insensitive mammalian target of rapamycin complex (mTORC2). Phosphorylation of
substrates by activated AKT subsequently results in a cascade of downstream signaling
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events. Mutations in PI3K that result in constitutive growth-factor-independent activation of
AKT are frequently observed in human cancers.1, 2
In addition to its established contribution to cancer progression, the PI3K/AKT pathway also
plays key roles in the infection and replication of certain viral pathogens. This pathway is
hijacked to promote host cell survival in cells infected by Influenza A virus3 and HIV-1,4 it
plays a critical role in the cellular entry of Ebola virus,5 and it has been hypothesized in
some studies,6, 7 but not others,8 to be involved in the replication of nonsegmented negative
stranded RNA viruses such as parainfluenza virus 5 (PIV5). Among the numerous small
molecules known to block the PI3K/AKT pathway, many inhibit AKT through interactions
with the ATP-binding site, allosteric sites, or the PH domain.9 Other inhibitors of this
pathway bind PI3K, other upstream components, kinases between PI3K and AKT, or
downstream proteins.10 AKT inhibitor-IV (1, also known as ChemBridge 5233705, Figure
1) was initially proposed to target the ATP binding site of unknown kinases upstream of
AKT but downstream of PI3K.11 In 786-O cells, 1 blocks AKT-mediated nuclear export of
the transcription factor FOXO1a (IC50 = 625 nM)11 and cell proliferation (IC50 < 1.25 μM).
12–15 More recent studies indicate that a low (1 μM) concentration of 1 inhibits
phosphorylation of substrates downstream of AKT, but the antiviral effects observed at this
concentration do not result from direct inhibition of kinase activity of the AKT1 or AKT2
subtypes or other known kinases of the PI3K pathway.8 Consequently, the mechanism of
antiviral and antiproliferative activities of 1 remains poorly understood, and molecular
probes that facilitate the identification of specific protein targets of this compound are
needed.
To better define the structural basis of its antiviral/antiproliferative activities, we report here
a new synthetic approach that allowed preparation of 1 and 21 related analogues. This route
is based on a ZrCl4-mediated cyclization reaction of substituted N-aryl 1,2-arylenediamines
with α,β-unsaturated aldehydes. We evaluated the in vitro antiviral activity of these
compounds against PIV5 in infected HeLa cells, examined the cytotoxic effects of the most
potent compounds against HeLa cells and normal human bronchial/tracheal epithelial
(NHBE) cells, and assessed effects on replication of the intracellular bacterium M. fortuitum
in HeLa cells. These studies identified two analogues with greater biological activity than
the parent compound and provide strategies for structural modification that may be valuable
for future target identification studies.
Results and discussion
Benzimidazole represents an important scaffold in natural products and is considered a
privileged structure in medicinal chemistry.16–18 Although numerous routes to
benzimidazoles have been reported,19 an efficient route for preparation of the commercially
available benzimidazole derivative AKT inhibitor-IV (1) has not been previously described.
For the synthesis of simpler benzimidazoles, unconjugated aldehydes can often be
condensed with 1,2-phenylenediamines to generate benzimidazoline intermediates20–22 that
can be further oxidized with mild oxidants such as potassium peroxymonosulfate,20
MnO2,23 and DDQ,24 to afford the desired products. However, the use of this approach with
sensitive α,β-unsaturated aldehyde substrates as building blocks for the preparation of more
complex benzimidazole derivatives such as 1 is known20, 23, 24 to be problematic. To
develop an improved route to these more sensitive derivatives, we initially synthesized the
novel 1,2-arylenediamine 7 (Scheme 1) in three steps from 4-chloro-3-nitrobenzaldehyde
(2). Compound 2 was condensed with 2-aminothiophenol (3) to generate benzothiazole 4
using conditions described by Mortimer for similar substrates.25 Treatment of 4 with freshly
distilled aniline (5) afforded 6, which was reduced with hydrazine in the presence of Pd(0)26
to yield 7. However, when 7 and the known27 α,β-unsaturated-γ-amino aldehyde 10 were
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subjected to well-precedented conditions for generating benzimidazolines, such as refluxing
in ethanol, the reaction was extremely sluggish. Moreover, subsequent addition of potassium
peroxymonosulfate,20 MnO2,23 or DDQ,24 resulted in decomposition, and complex reaction
mixtures were obtained. To provide better methodology for the preparation of
benzimidazoles using α,β-unsaturated aldehyde coupling partners, we alternatively executed
the cyclization and oxidation steps separately. We found that in the presence of 3Å
molecular sieves, the benzimidazoline intermediate 11 was generated as a major byproduct
in refluxing ethanol, and MnO2 was sufficiently mild to afford 12, but unfortunately this
reaction generated only low yields of the desired product 12. To improve this outcome, we
examined the use of Lewis acids such as ZrOCl2, ZrCl4, CuSO4, and FeCl3 previously
reported28–31 for the preparation of benzimidazoles, benzothiazoles, and purines. By
screening a variety of Lewis acids, we found that addition of 0.5 equivalents of ZrCl4 to 7
and 10 in refluxing ethanol afforded 11, which could be oxidized in situ with MnO2 to
afford 12 in a remarkably high 75% yield. As shown in Scheme 1, alkylation of 12 with
excess ethyl iodide followed by purification by flash column chromatography afforded AKT
inhibitor-IV (1). Analogues 13-32, shown in Figure 2, were prepared by this zirconium-
mediated cyclization route or similar methods as illustrated in Schemes 2 and 3.
To examine the antiviral activity of compounds 12-32, we constructed a recombinant
parainfluenza virus 5 minigenome system (rPIV5-RL). As shown in Figure 3, this system is
analogous to a previously reported32 recombinant PIV5 that expresses GFP, but we replaced
the gene encoding GFP with renilla luciferase (RL), which was inserted into the viral
genome between the HN and L genes. To validate the utility of rPIV5-RL for testing
compounds related to 1, we quantified luciferase activity in infected HeLa cells, a human
cervical carcinoma line suitable for virus replication, as a function of multiplicity of
infection (MOI). The strong correlation of MOI with luciferase activity, as shown in Figure
3, confirmed the utility of rPIV5-RL for evaluation of antiviral activity of synthetic
compounds. Assessment of antiviral activity initially involved infection of HeLa cells with
rPIV5-RL at 1 MOI followed by treatment with compounds 1 and 12-32 at 1 μM to generate
singleton data points. As shown in Figure 4, compounds comparable in activity to 1 at this
concentration were further studied at 0.5 μM as singletons. Dose-response curves against
rPIV5-RL and cytotoxic effects towards HeLa cells were used to generate IC50 values for 1
and the three most potent analogues (29-31, Figure 5). Importantly, two compounds were
identified (30, 31) that exhibit greater antiviral activity than the parent compound 1.
However, the cytotoxicity of all of these compounds towards HeLa cancer cells, assessed by
quantifying cellular ATP using a firefly luciferase-based assay, generally paralleled their
antiviral activity. Interestingly, 6-fold (for 1) to >20-fold (for 31) higher concentrations of
these compounds were required for comparable cytotoxic effects against NHBE cells,
suggesting the possibility of inhibition of one or more host protein(s) required for
proliferation of cancer cells and PIV5. Control experiments examining inhibition of both
renilla luciferase and firefly luciferase present in cell extracts confirmed that the observed
biological activity does not result from inhibition of either these reporter enzymes (data
provided in the supporting information). To further confirm that the biological activity of
analogues 29-31 does not relate to non-specific detergent-like action, we evaluated the effect
of these compounds on replication of intracellular M. fortuitum bacteria in infected HeLa
cells. Whereas the non-ionic detergent Triton X-100 (1%) reduced bacterial survival by 18-
fold compared with DMSO vehicle alone, no deleterious effects of 1 or 29-31 (0.5 μM) on
bacterial replication was observed. Together, these results suggest that 1 and the potent
analogues 29-31 selectively inhibit one or more mammalian host proteins necessary for both
proliferation of HeLa cervical carcinoma cells and replication of PIV5.
How AKT inhibitor-IV (1) affects the PI3K/AKT pathway is not well understood. In studies
of the relatively high concentration of 10 μM, 1 was originally proposed by Silver11 to target
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the ATP binding site of unknown kinases upstream of AKT but downstream of PI3K.
However, a more recent investigation8 by Connor of cells treated with 1 μM of 1 indicates
that this compound exhibits potent antiviral and antiproliferative effects through a unique
mechanism that does not involve inhibition of the AKT1 or AKT2 subtypes or inhibition of
other known kinases within the PI3K/AKT pathway. At 1 μM, 1 is known to promote
hyperphosphorylation of AKT in multiple mammalian cell lines, a process that requires
PI3K activity, and could potentially involve activation of the PDK1 kinase directly upstream
of AKT.8 Additionally, in a high-throughput screening assay against 84 kinases, 1 (1 μM)
showed no inhibitory activity against 82 of these enzymes, and only slight inhibition of the
AGC kinases SGK1 and MKK1 was observed.8 However, treatment of cells with 1 is known
to decrease phosphorylation of AKT substrates such as 4E-BP-1, suggesting that inhibition
occurs downstream of AKT kinase, possibly implicating mTORC2 as a target.8 Inhibition or
activation of other aspects of normal cellular function outside of the PI3K/AKT pathway
may also play key roles in the potent biological activities of 1.8
In conclusion, we synthesized the potent antiviral/antiproliferative agent AKT inhibitor-IV
(1) by developing a zirconium-mediated condensation approach that allows coupling of the
sensitive α,β-unsaturated aldehydes with the novel 1,2-arylenediamine 7. This methodology
allowed the preparation of a collection of 21 analogues. Evaluation of these analogues
identified two compounds (30, 31) with greater activity than 1 against recombinant PIV5
expressing luciferase in HeLa cells. Although these compounds were found to exhibit potent
cytotoxic activity against HeLa carcinoma cells, this toxicity was 6-fold to >20-fold lower
against normal NHBE cells, and no effect against replication of intracellular M. fortuitum
bacteria was observed, suggesting the possibility of selective inhibition of unidentified host
protein(s) involved in proliferation of cancer cells and PIV5. The ability to substitute AKT
inhibitor-IV (1) with long side chains at the N3 position without deleteriously affecting its
antiviral and cytotoxic activity may be useful for future affinity chromatography33 or related
methods directed at identification of protein target(s) of AKT inhibitor-IV (1).
Experimental Section
General
Chemical reagents and solvents were obtained from Acros, Aldrich, EMD Biosciences and
Combi-Blocks. Commercial grade reagents were used without further purification unless
otherwise noted. Compounds 1027 and 3334 were prepared using previously described
methods. Compounds 35 and 36 were prepared by converting 4-chloro-3-nitro-benzoic acid
to the acid chloride with thionyl chloride followed by reaction with methanol and aniline,
respectively. Anhydrous solvents were obtained after passage through a drying column of a
solvent purification system from GlassContour (Laguna Beach, CA). All reactions were
performed under an atmosphere of dry nitrogen. Reactions were monitored by analytical
thin-layer chromatography on plates coated with 0.25 mm silica gel 60 F254 (EMD
Chemicals). TLC plates were visualized by UV irradiation (254 nm) or stained with 20%
phosphomolybdic acid in ethanol. Flash column chromatography employed silica gel (ICN
SiliTech, 32–63 μm). Melting points were measured with a Thomas Hoover capillary
melting point apparatus and are uncorrected. Infrared spectra were obtained with a Perkin
Elmer 1600 Series FTIR. NMR spectra were obtained with Bruker CDPX-300 and AV-400
instruments with chemical shifts reported in parts per million (ppm, δ). High-resolution mass
spectra were obtained from the proteomics and mass spectrometry core facility at Penn State
University, University Park, PA or the mass spectrometry facility at the University of
Kansas. Peaks are reported as m/z. Analytical purity of compounds was determined by
analytical reverse-phase HPLC with a PRP-1 (polystyrene-divinylbenzene) reverse-phase
column (4.1 × 250 mm, 7 μm; Hamilton) running a gradient of 10% to 99.9% CH3CN in
nanopure water (containing 0.1% TFA) over 20 min at a flow rate of 0.8 mL/min. All
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compounds subjected to biological assays were ≥98% pure by analytical reverse phase
HPLC.
2-(4-Chloro-3-nitro-phenyl)-benzothiazole (4)
To a solution of compound 2 (5.5 g, 30 mmol) in anhydrous ethanol (250 mL) was added 2-
aminothiophenol (3, 3.3 mL, 30 mmol). The reaction was refluxed for 16 h and cooled to 22
°C. A white precipitate was collected by filtration with a fritted funnel, and the solid crude
product was washed with cold ethanol (10 mL × 3). Recrystallization from toluene afforded
the product (6.26 g, 72%) as an off white solid; mp 163–164 °C; Rf = 0.51 (hexane/ethyl
acetate, 3:1); 1H NMR (400 MHz, DMSO-d6) δ 8.72 (s, 1H), 8.35 (d, 1H, J = 8.4 Hz), 8.21
(d, 1H, J = 8.0 Hz), 8.12 (d, 1H, J = 8.0 Hz), 7.96 (d, 1H, J = 8.4 Hz), 7.58 (dd, 1H, J = 8.4
Hz), 7.52 (dd, 1H, J = 8.4 Hz); 13C NMR (100 MHz, DMSO-d6) δ 164.3, 153.7, 148.6,
135.4, 133.4, 133.2, 132.3, 127.8, 127.6, 126.8, 124.1, 123.8, 123.2; IR (film) ν max 1604,
1566, 1538, 1456, 1430, 1339, 1127, 1050, 990, 887, 835, 764, 730 cm−1; HRMS (ESI-) m/z
288.9831 (M-H−, C13H6ClN2O2S requires 288.9839).
(4-Benzothiazol-2-yl-2-nitrophenyl)phenylamine (6)
To a solution of compound 4 (2.9 g, 10 mmol) in DMSO (50 mL) was added freshly
distilled aniline (5, 4.6 mL, 50 mmol). The reaction was heated to 70 °C and stirred for 8 h.
The reaction was cooled to 22 °C and poured into water (200 mL). The aqueous phase was
extracted with diethyl ether (100 mL × 4). The organic extracts were combined and washed
with saturated aqueous NaCl (200 mL), dried over anhydrous Na2SO4, and concentrated in
vacuo. The residue was purified by column chromatography (CH2Cl2 eluent) to afford the
product (2.46 g, 71%) as a orange solid; mp 160–162 °C; Rf = 0.56 (hexane/ethyl acetate,
3:1); 1H NMR (300 MHz, CDCl3) δ 9.75 (s, 1H), 8.86 (d, 1H, J = 2.1 Hz), 8.07 (dd, 1H, J1
= 2.1 Hz, J2 = 9.0 Hz), 8.00 (d, 1H, J = 8.1 Hz), 7.86 (d, 1H, J = 9 Hz), 7.49-7.44 (m, 3H),
7.36-7.25 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 165.6, 156.6, 144.5, 137.8, 134.7, 134.0,
132.7, 129.9 (× 2), 126.5, 126.4, 126.0, 125.2, 124.8 (× 2), 123.3, 123.0, 121,6, 116.4; IR
(film) ν max 3333, 1624, 1594, 1567, 1531, 1496, 1353, 1266, 1210, 753 cm−1; HRMS (ESI
+) m/z 348.0833 (M+H+, C19H14N3O2S requires 348.0807).
4-Benzothiazol-2-yl-N1-phenylbenzene-1,2-diamine (7)
To a slurry of compound 6 (1.74 g, 5 mmol) in ethanol (50 mL) was added palladium on
carbon (10%, 530 mg, 0.5 mmol) and anhydrous hydrazine (0.5 mL, 16 mmol). The reaction
was heated to 80 °C and refluxed for 30 min. The reaction was cooled to 22 °C and filtered
through a fritted funnel. The solid Pd/C was washed with ethanol (10 mL), and the
combined filtrate was concentrated in vacuo to afford the crude product. Recrystallization
from CH2Cl2/hexane afforded the product (1.52 g, 95%) as a light yellow solid; mp 154–156
°C; Rf = 0.13 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, DMSO-d6) δ 8.06 (d, 1H, J =
7.5 Hz), 7.97 (d, 1H, J = 7.7 Hz), 7.55 (d, 1H, J = 2.0 Hz), 7.52-7.46 (m, 1H) 7.44 (s, 1H)
7.41-7.36 (m, 1H) 7.29-7.19 (m, 4H), 7.01 (d, 2H, J = 8 Hz) 6.83 (t, 1H, J = 7.3 Hz), 5.17 (s,
2H); 13C NMR (75 MHz, DMSO-d6) δ 168.0, 153.8, 143.7, 140.2, 134.1, 132.3, 129.1 (× 2),
126.4, 126.3, 124.8, 122.2, 122.1, 119.7, 118.4, 117.0 (× 2), 116.4, 113.2; IR (film) ν max
3360, 3037, 1595, 1496, 1434, 1313, 1194, 1000, 810, 749, 728, 693 cm−1; HRMS (ESI+)
m/z 318.1066 (M+H+, C19H16N3S requires 318.1065).
[(E)-2-(5-Benzothiazol-2-yl-1-phenyl-1H-benzoimidazol-2-yl)ethenyl]methyl phenylamine
(12)
To a solution of compound 7 (64 mg, 0.2 mmol) and 10 (32 mg, 0.2 mmol) in anhydrous
ethanol (15 mL) was added ZrCl4 (24 mg, 0.1 mmol). The reaction was heated to 80 °C and
refluxed for 30 min. When the starting material was consumed as evidenced by TLC, MnO2
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(70 mg, 0.8 mmol) was added and the reaction was stirred at room temperature (22 °C) for 5
min. The reaction was cooled and filtered through a fritted funnel. The solid MnO2 was
washed with ethanol (10 mL), and the combined filtrate was concentrated in vacuo. Flash
column chromatography (hexane/ethyl acetate, 4:1) afforded the product (68 mg, 75%) as a
yellow solid; mp 215–217 °C; Rf = 0.13 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz,
CDCl3) δ 8.34 (s, 1H), 8.31 (d, 1H, J = 0.9 Hz), 8.05 (d, 1H, J = 6.0 Hz), 7.99 (dd, 1H, J1 =
1.2 Hz, J2 = 6.3 Hz), 7.89 (d, 1H, J = 5.8 Hz), 7.64-7.44 (m, 5H), 7.34 (dd, 3H, J1 = 5.6 Hz,
J2 = 6.0 Hz), 7.18 (d, 2H, J = 5.8 Hz), 7.13 (d, 1H, J = 6.3 Hz), 7.08 (t, 1H, J = 5.5 Hz), 5.22
(d, 1H, J = 9.9 Hz), 3.19 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.8, 155.9, 154.8, 147.0,
143.2 (× 2), 139.1, 136.2, 135.5, 130.4 (× 2), 129.8 (× 2), 129.2, 128.7, 128.0 (× 2), 126.4,
125.1, 123.9, 121.9, 121.3, 119.8, 117.7, 114.9, 111.7, 109.9 87.5, 36.5; IR (film) ν max
3059, 2944, 2901, 1627, 1594, 1492, 1464, 1435, 1347, 1298, 1270, 1127, 978, 910, 758,
730, 696 cm−1; HRMS (ESI+) m/z 459.1663 (M+H+, C29H23N4S requires 459.1643).
5-Benzothiazol-2-yl-3-ethyl-2-[(E)-2-(methylphenylamino)ethenyl]-1-phenyl-3H-benzo-
imidazol-1-ium, iodide (1)
A slurry of 12 (35 mg, 0.076 mmol) in ethyl iodide (76, 3 mL) was heated to 75 °C and
refluxed for 24 h. The solvent was removed in vacuo. The crude product was purified by
flash column chromatography (CH2Cl2/MeOH, 20:1) to afford the product (41 mg, 88%) as
a yellow solid; mp 165–167 °C; Rf = 0.18 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz,
MeOH-d4) δ 8.43 (s, 1H), 8.10-8.00 (m, 3H), 7.83-7.69 (m, 5H), 7.53-7.14 (m, 7H), 6.74 (d,
J = 6.5 Hz, 2H), 5.52 (d, J = 12.3 Hz, 1H), 4.61 (q, J = 7.1 Hz, 2H), 3.41 (s, 3H), 1.61 (t, J =
7.1 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 167.2, 154.1, 152.1, 150.7 (× 2), 135.9,
135.3, 135.0, 132.1, 131.9 (× 2), 131.5, 131.2, 129.7 (× 2), 128.1 (× 2), 127.0, 126.3, 126.0,
125.5, 123.0, 122.1, 120.4 (× 2), 112.0 (× 2), 109.6, 78.2, 40.3, 12.9; IR (film) ν max 3290,
3058, 2924, 1688, 1618, 1507, 1537, 1494, 1465, 1371, 1308, 1203, 1132, 1029, 800, 763,
697 cm−1; HRMS (ESI+) m/z 487.1949, (M+H+, C31H27N4S requires 487.1956).
(4-Benzooxazol-2-yl-2-nitrophenyl)phenylamine (40)
2-(4-Chloro-3-nitro-phenyl)benzooxazole (33, 1.2 g, 4.5 mmol) and freshly distilled aniline
(1.8 mL, 20 mmol) were used to synthesize 40 using the procedure described for preparation
of 6. Column chromatography (CH2Cl2) afforded the product (2.24 g, 84%) as a orange
solid, mp 164–166 °C; Rf = 0.15 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ
9.82 (s, 1H), 9.09 (s, 1H), 8.20 (d, J = 9.0 Hz, 1H), 7.73 (m, 1H), 7.57 (m, 1H), 7.52-7.47
(m, 2H), 7.36-7.29 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 161.3, 150.6, 144.9, 142.0,
137.6, 134.0, 132.6, 130.0 (× 2), 126.7, 126.4, 125.1, 125.0 (× 2), 124.7, 119.7, 116.4 (× 2),
110.5; IR (film) ν max 3339, 1628, 1596, 1507, 1452, 1352, 1264, 1242, 1152, 1077 cm−1;
HRMS (ESI+) m/z 332.1035 (M+H+, C19H14N3O3 requires 332.1035).
(2-Nitrophenyl)phenylamine (41)
1-Chloro-2-nitrobenzene (34, 1.57 g, 10 mmol) and freshly distilled aniline (2.7 mL, 30
mmol) were used to synthesize 41 using the procedure described for preparation of 6.
Column chromatography (CH2Cl2) afforded the product (1.58 g, 74%) as a orange solid, mp
73–75 °C; Rf = 0.18 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 9.50 (s, br,
1H), 8.20 (dd, J1 = 7.6 Hz, J2 = 1.4 Hz, 1H), 7.46-7.21 (m, 7H) 6.78 (m, 1H); 13C NMR (75
MHz, CDCl3) δ 143.1, 138.7, 135.7, 133.2, 129.7, 126.7, 125.6, 124.4, 117.5, 116.0; IR
(film) ν max 3389, 1630, 1591, 1576, 1508, 1452, 1415, 1351, 1262, 1241, 1153, 1076
cm−1. HRMS (ESI+) m/z 215.0822 (M+H+, C12H11N2O2 requires 215.0821).
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3-Nitro-4-phenylaminobenzoic acid methyl ester (42)
4-Chloro-3-nitrobenzoic acid methyl ester (35, 2.15 g, 10 mmol) and freshly distilled aniline
(2.7 mL, 30 mmol) were used to synthesize 42 using the procedure described for preparation
of 6. Column chromatography (CH2Cl2) afforded the product (2.37 g, 87%) as a yellow
solid, mp 121–123 °C; Rf = 0.48 (hexane/ethyl acetate, 3:1); 1H NMR (400 MHz, CDCl3) δ
9.81 (s, br, 1H), 8.93 (d, J = 2.0 Hz, 1H), 7.97 (dd, J1 = 8.9 Hz, J2 = 2.1 Hz, 1H), 7.48 (dd,
J1 = J2 = 7.6 Hz, 2H), 7.32 (m, J1 = 8.9 Hz, J2 = 2.1 Hz, 3H), 7.17 (d, J = 9.0 Hz, 1H), 3.92
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 165.4, 146.0, 137.6, 135.9, 132.2, 129.8 (× 2),
129.3, 126.8, 125.1 (× 2), 119.2, 115.6; IR (film) ν max 3337, 2951, 1718, 1624, 1596,
1567, 1524, 1497, 1436, 1354, 1312, 1281, 1212, 1151, 1119, 1071, 987, 918, 756, 692
cm−1; HRMS (ESI+) m/z 273.0851 (M+H+, C14H13N2O4 requires 273.0875).
3-Nitro-N-phenyl-4-phenylaminobenzamide (43)
4-Chloro-3-nitro-N-phenylbenzamide (2.2 g, 8 mmol) and freshly distilled aniline (3.7 mL,
40 mmol) were used to synthesize 43 using the procedure described for preparation of 6.
Flash column chromatography (hexane/ethyl acetate, 8:1) afforded the product (2.24 g,
84%) as a orange solid, mp 212–215 °C; Rf = 0.16 (hexane/ethyl acetate, 3:1); 1H NMR
(300 MHz, CDCl3) δ 9.81 (s, 1H), 8.74 (d, J = 1.5 Hz, 1H), 7.98 (dd, J1 = 1.3 Hz, J2 = 6.7
Hz, 1H), 7.79 (s, 1H), 7.66 (d, J = 5.9 Hz, 2H), 7.50 (t, J = 5.9 Hz, 2H), 7.43 (t, J = 5.6 Hz,
2H), 7.34-7.27 (m, 3H), 7.19 (t, J = 5.6 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 165.8,
144.1, 139.8, 139.6, 131.9, 129.0 (× 2), 128.8, 128.5 (× 2), 123.1, 120.1 (× 2), 119.3, 118.3,
116.5 (× 2), 116.3, 114.7; IR (film) ν max 3331, 1648, 1623, 1596, 1440, 1319, 1267, 1214,
1152, 753, 690 cm−1; HRMS (ESI+) m/z 334.1181 (M+H+, C19H16N3O3 requires
334.1192).
4-Benzooxazol-2-yl-N1-phenylbenzene-1,2-diamine (47)
Compound 40 (900 mg, 2.7 mmol) was treated with anhydrous hydrazine (0.5 mL, 16
mmol) and Pd/C (318 mg, 0.3 mmol) using the procedure described for preparation of 7.
Flash column chromatography (hexane/ethyl acetate, 6:1) afforded the product (758 mg,
93%) as a yellow solid; Rf = 0.53 (hexane/ethyl acetate, 1:1); mp 142–143 °C; 1H NMR
(300 MHz, CDCl3) δ 7,79-7.69 (m, 3H), 7.60-7.57 (m, 1 H), 7.37-7,29 (m, 5H), 7.01-6.98
(m, 3H), 5,60 (s, 1H), 3.65 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 163.4, 150.6, 142.9,
142.2, 138.7, 134.2, 129.4 (× 2), 124.6, 124.4, 121.6, 121.1, 119.7, 119.7, 119.5, 117.6 (×
2), 115.6, 110.5; IR (film) ν max 3364, 3048, 1614, 1594, 1557, 1497, 1454, 1313, 1244,
744 cm−1; HRMS (ESI+) m/z 302.1302 (M+H+, C19H16N3O requires 302.1293).
N-Phenylbenzene-1,2-diamine (48)
Compound 41 (1.07 g, 5.0 mmol) was treated with anhydrous hydrazine (0.75 mL, 24
mmol) and Pd/C (530 mg, 0.5 mmol) using the procedure described for preparation of 7.
Flash column chromatography (hexane/ethyl acetate, 8:1) afforded the product (840 mg,
91%) as a yellow solid; Rf = 0.65 (hexane/ethyl acetate, 1:1); mp 77–79 °C; 1H NMR (300
MHz, CDCl3) δ 7.19 (dd, J1 = 7.6 Hz, J2 = 8.5 Hz, 2H), 7.10 (dd, J1 = 7.9 Hz, J2 = 1.5 Hz,
1H), 7.00 (dd, J1 = J2 = 7.2 Hz, 1H), 6.81-6.71 (m, 5H), 5,15 (s, br, 1H), 3.70 (s, br,
2H); 13C NMR (75 MHz, CDCl3) δ145.3, 141.9, 129.2 (× 2), 128.5, 125.6, 124.9, 119.2,
119.0, 116.1, 115.1 (× 2); IR (film) ν max 3445, 3388, 3360, 3048, 1604, 1594, 1502, 1461,
1323, 1265, 1254 cm−1; HRMS (ESI+) m/z 185.1075 (M+H+, C12H12N2 requires
185.1073).
3-Amino-4-phenylaminobenzoic acid methyl ester (49)
Compound 42 (816 mg, 3.0 mmol) was treated with anhydrous hydrazine (0.5 mL, 16
mmol) and Pd/C (318 mg, 0.3 mmol) using the procedure described for preparation of 7.
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Flash column chromatography (hexane/ethyl acetate, 6:1) afforded the product (675 mg,
93%) as a white solid; Rf = 0.45 (hexane/ethyl acetate, 1:1); mp 89–90 °C; 1H NMR (400
MHz, DMSO-d6) δ 7.39 (s, 1H), 7.35 (d, J = 2.0 Hz, 1H), 7.24 (dd, J1 = J2 = 7.6 Hz, 2H),
7.15 (dd, J1 = 2.0 Hz, J2 = 7.6 Hz, 1H), 7.07 (d, J1 = 7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 2H),
6.85 (dd, J = 7.6 Hz, 1H), 3.77 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 167.0, 143.6,
139.2, 134.5, 129.6 (× 2), 122.5, 120.6, 119.1, 118.1 (× 2), 116.8, 116.1, 52.0; IR (film) ν
max 3368, 3049, 2949, 1698, 1594, 1518, 1497, 1447, 1311, 1252, 1112, 1079, 993, 887,
763, 749, 695 cm−1; HRMS (ESI+) m/z 243.1136 (M+H+, C14H15N2O2 requires 243.1134).
3-Amino-N-phenyl-4-phenylaminobenzamide (50)
Compound 43 (1.0 g, 3.0 mmol) was treated with anhydrous hydrazine (0.5 mL, 16 mmol)
and Pd/C (318 mg, 0.3 mmol) using the procedure described for preparation of 7. Flash
column chromatography (hexane/ethyl acetate, 6:1) afforded the product (875 mg, 96%) as a
white solid; Rf = 0.53 (hexane/ethyl acetate, 1:1); mp 176–178 °C; 1H NMR (300 MHz,
DMSO-d6) δ 7.76 (d, J = 7.6 Hz, 2H), 7.34-7.29 (m, 4H), 7.23-7.10 (m, 4H), 7.05 (t, J = 7.4
Hz, 1H), 6.93 (d, J = 7.6 Hz, 2H), 6.79 (t, J = 7.2 Hz, 1H), 5.0 (s, 2H), 7.19 (t, J = 5.6 Hz,
1H); 13C NMR (75 MHz, DMSO-d6) δ 165.8, 144.1, 139.8, 139.6, 131.9, 129.1 (× 2), 128.8,
128.5 (× 2), 123.1, 120.1 (× 2), 119.3, 118.3, 116.5 (× 2), 116.4, 114.7; IR (film) ν max
3324, 1643, 1594, 1497, 1434, 1316, 1241, 886, 774, 691 cm−1; HRMS (ESI+) m/z
304.1457 (M+H+, C19H18N3O requires 304.1450).
[(E)-2-(5-Benzooxazol-2-yl-1-phenyl-1H-benzoimidazol-2-yl)ethenyl]methylphenylamine (61)
Compound 47 (60 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24 mg, 0.1 mmol)
were used to synthesize 61 using the procedure described for preparation of 12. Flash
column chromatography (hexane/ethyl acetate, 5:1) afforded the product (48 mg, 54%) as a
light yellow solid; mp 194–196 °C; Rf = 0.54 (hexane/ethyl acetate, 1:1); 1H NMR (300
MHz, CDCl3) δ 8.55 (d, J = 1.1 Hz, 1H), 8.35 (d, J = 13.2 Hz, 1H), 8.09 (dd, J1 = 1.5 Hz, J2
= 8.4 Hz, 1H), 7.78 (m, 1H), 7.68-7.54 (m, 4 H), 7.51-7.49 (m, 2H), 7.39-7.31 (m, 4H),
7.21-7.02 (m, 4H), 5.36 (d, J = 13.2 Hz, 1H), 3.15 (s, 3H); 13C NMR (75 MHz, CDCl3) δ
164.3, 155.6, 150.8, 146.6, 142.8, 142.4, 140.0, 135.7, 130.0 (× 2), 129.3 (× 3), 128.9, 127.6
(× 2), 124.4, 124.3, 123.5, 121.4, 121.4, 119.6, 119.4 (× 2), 117.1, 110.4, 109.5, 87.0, 36.1;
IR (film) ν max 3060, 1627, 1594, 1582, 1492, 1453, 1347, 1297, 1244, 1127, 746, 696
cm−1; HRMS (ESI+) m/z 443.1875 (M+H+, C29H23N4O requires 443.1872).
Methyl-phenyl-[(E)-2-(1-phenyl-1H-benzoimidazol-2-yl)ethenyl]amine (62)
N-Phenylbenzene-1,2-diamine (48, 37 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24
mg, 0.1 mmol) were used to synthesize 62 using the procedure described for preparation of
12. Flash column chromatography (hexane/ethyl acetate, 5:1) afforded the product (39 mg,
61%) as a yellow solid; mp 118–121 °C; Rf = 0.54 (hexane/ethyl acetate, 1:1); 1H NMR
(300 MHz, CDCl3) δ 8.30 (d, J = 13.3 Hz, 1H), 7.71(d, J = 7.9 Hz, 1H), 7.64-7.46 (m, 5H),
7.34 (t, J = 7.9 Hz, 2H), 7.25-7.05 (m, 6H), 5.26 (d, J = 13.3 Hz, 1H), 3.20 (s, 3H); 13C
NMR (75 MHz, CDCl3) δ 153.8, 146.7, 142.0, 136.5, 136.3, 129.8 (× 2), 129.3 (× 2), 128.5,
127.6 (× 2), 123.1, 122.4, 121.1, 119.2 (× 2), 117.6, 109.2 (× 2), 87.6, 35.9; IR (film) ν max
3060, 1629, 1594, 1492, 1454, 1347, 1301, 1286, 1267, 1127, 757, 695 cm−1; HRMS (ESI
+) m/z 326.1651 (M+H+, C22H20N3 requires 326.1657).
2-[(E)-2-(Methylphenylamino)ethenyl]-1-phenyl-1H-benzoimidazole-5-carboxylic acid
methyl ester (63)
3-Amino-4-phenylaminobenzoic acid methyl ester (49, 48 mg, 0.2 mmol), 10 (32 mg, 0.2
mmol), and ZrCl4 (24 mg, 0.1 mmol) were used to synthesize 63 using the procedure
described for preparation of 12. Flash column chromatography (hexane/ethyl acetate, 5:1)
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afforded the product (50 mg, 65%) as a light yellow solid; mp 169–170 °C; Rf = 0.64
(hexane/ethyl acetate, 1:1); 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 1.3 Hz, 1H), 8.28 (d,
J = 13.3 Hz, 1H), 7.82 (dd, J1 = 1.5 Hz, J2 = 8.4 Hz, 1H), 7.63-7.53 (m, 3H), 7.45-7.43 (m,
2H), 7.33 (t, J = 7.4 Hz, 2H), 7.15 (d, J = 7.7 Hz, 2H), 7.07 (m, 2H), 5.20 (d, J = 13.3 Hz,
1H), 3.93 (s, 3H), 3.17 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 167.9, 155.7, 146.6, 143.3,
142.7, 139.9, 135.8, 130.0 (× 2), 129.3 (× 2), 128.8, 127.5 (× 2), 124.4, 123.5, 123.0, 119.6,
119.3 (× 2), 108.6, 87.1, 52.0, 36.1; IR (film) ν max 1712, 1628, 1492, 1438, 1348, 1297,




Compound 50 (61 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24 mg, 0.1 mmol)
were used to synthesize 64 using the procedure described for preparation of 12. Flash
column chromatography (hexane/ethyl acetate, 5:1) afforded the product (50 mg, 56%) as a
yellow solid; mp 121–123 °C; Rf = 0.50 (hexane/ethyl acetate, 1:1); 1H NMR (300 MHz,
MeOH-d4) δ 8.28 (d, J = 17.3 Hz, 1H), 8.12(s, 1H), 7.72-7.07 (m, 18H), 5.21 (d, J = 13.4
Hz, 1H), 3.16 (s, 3H); 13C NMR (75 MHz, MeOH-d4) δ 169.3, 158.3, 157.5, 148.0, 144.5,
143.7, 140.1, 140.0, 136.8, 131.4 (× 2), 130.8, 130.6 (× 2), 130.5, 129.8 (× 2), 128.7, 125.4,
124.8, 122.6, 122.4 (× 2), 120.3 (× 2), 117.4, 110.2, 87.1, 36.3; IR (film) ν max 3290, 3059,
1625, 1595, 1540, 1498, 1433, 1316, 1297, 1127, 751 cm−1; HRMS (ESI+) m/z 445.2021
(M+H+, C29H25N4O requires 445.2028).
5-Benzooxazol-2-yl-3-ethyl-2-[(E)-2-(methylphenylamino)ethenyl]-1-phenyl-3H-
benzoimidazol-1-ium, iodide (16)
Compound 61 (35 mg, 0.079 mmol) and ethyl iodide (3 mL) were used to synthesize 16
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (40 mg, 86%) as a yellow solid, mp 181–184 °C; Rf =
0.22 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, CDCl3) δ 8.75 (s, 1H), 8.44 (d, J = 12.2
Hz, 1H), 7.71-7.56 (m, 7H), 7.31-7.03 (m, 7H), 6.52 (m, 2H), 5.41 (d, J = 11.6 Hz, 1H), 4.50
(q, J = 6.7 Hz, 2H), 3.17 (s, 3H), 1.50 (t, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ
163.4, 153.3, 152.2, 151.8, 142.9, 137.3, 136.0, 132.9 (× 3), 132.6, 130.7 (× 3), 129.2 (× 3),
127.3, 127.0, 126.3, 126.2, 125.4, 120.8, 113.1, 111.9, 111.3, 79.1, 41.1, 36.9, 13.9; IR
(film) ν max 3425, 1681, 1617, 1586, 1537, 1494, 1453, 1365, 1298, 1197, 1136, 761, 697
cm−1; HRMS (ESI+) m/z 471.2168 (M+, C31H27N4O requires 471.2185).
1-Ethyl-2-[(E)-2-(methylphenylamino)ethenyl]-3-phenyl-3H-benzoimidazol-1-ium, iodide (15)
Compound 62 (30 mg, 0.092 mmol) and ethyl iodide (3 mL) were used to synthesize 15
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (37 mg, 85%) as a yellow solid; mp 43–45 °C; Rf = 0.28
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 7.83-7.77 (m, 4H), 7.69-7.66(m,
2H), 7.52 (t, J = 7.2, 1H), 7.44 (t, J = 7.3 Hz, 1H), 7.31-7.08 (m, 5H), 6.74 (d, J = 7.9 Hz,
2H), 5.56 (d, J = 11.3 Hz, 1H), 4.58 (d, J = 7.3 Hz, 2H), 3.41 (s, 3H), 1.58 (t, J = 7.3 Hz,
3H); 13C NMR (75 MHz, MeOH-d4) δ 152.1, 151.6, 151.5, 147.6, 136.8, 135.5, 133.2 (× 2),
132.9, 132.7, 131.1 (× 2), 129.7 (× 2), 127.4, 127.3, 127.2, 121.8, 112.9, 112.8, 79.5, 41.6,
37.5, 14.4; IR (film) ν max 3360, 1688, 1623, 1585, 1533, 1494, 1361, 1310, 1201, 1177,
1129, 759, 697 cm−1; HRMS (ESI+) m/z 354.1949 (M+, C24H24N3 requires 354.1970).
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Compound 63 (30 mg, 0.078 mmol) and ethyl iodide (3 mL) were used to synthesize 14
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (39 mg, 93%) as a yellow solid, mp 43–46 °C; Rf = 0.25
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.02 (dd, J1 = 8.6
Hz, J2 = 1.2 Hz, 1H), 7.84-8.63 (m, 5H), 7.29 (t, J = 8.1 Hz, 2H), 7.21-7.14 (m, 3H), 6.70
(d, J = 7.9 Hz, 2H), 5.76 (d, J = 13.5 Hz, 1H), 4.70 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 3.41 (s,
3H), 1.46 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 165.6, 152.0, 149.5, 145.2,
136.6, 134.5, 131.5 (× 2), 131.1, 130.9, 129.5 (× 3), 128.0 (× 2), 126.5, 126.4, 125.6, 119.6,
112.7, 111.3, 79.1, 52.5, 39.4, 36.4, 13.7; IR (film) ν max 3412, 1716, 1692, 1622, 1588,
1538, 1621, 1588, 1538, 1494, 1463, 1373, 1312, 1290, 1266, 1198, 1134, 764, 698 cm−1;
HRMS (ESI+) m/z 412.2000 (M+, C26H26N3O2 requires 412.2028).
3-Ethyl-2-[(E)-2-(methylphenylamino)ethenyl]-1-phenyl-5-phenylcarbamoyl-3H-
benzoimidazol-1-ium, iodide (18)
Compound 64 (35 mg, 0.079 mmol) and ethyl iodide (3 mL) were used to synthesize 18
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (40 mg, 84%) as a yellow solid, mp 285–287 °C
(decomp.); Rf = 0.44 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, DMSO-d6) δ 10.4 (s, 1H),
8.52(s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.82 (m, 7H), 7.40 (t, J = 7.4 Hz, 2H), 7.32 (t, J = 7.2
Hz, 2H), 7.24-7.15 (m, 4H), 6.73 (d, J = 7.6 Hz, 2H), 5.77 (d, J = 12.8 Hz), 4.69 (q, J = 6.5
Hz, 2H), 3.43 (s, 3H), 1.53 (t, J = 6.2 Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 164.8,
152.0, 149.7, 145.6, 139.3, 135.8, 134.9, 132.2, 131.9 (× 2), 131.4, 131.1, 129.9 (× 2), 129.1
(× 2), 128.4 (× 2), 125.9, 125.7, 124.4, 121.0 (× 2), 119.9 (× 2), 111.6, 111.3, 79.6, 40.9,
36.8, 14.2; IR (film) ν max 3260, 1662, 1620, 1587, 1525, 1493, 1463, 1440, 1369, 1306,
1251, 1128, 1209, 758 cm−1; HRMS (ESI+) m/z 473.2335 (M+, C31H29N4O requires
473.2341).
2-(1,2-Diphenyl-1H-benzoimidazol-5-yl)benzothiazole (68)
Compound 7 (64 mg, 0.2 mmol) and benzaldehyde (20 mL, 0.2 mmol) were used to
synthesize 68 using the procedure described for preparation of 12. Flash column
chromatography (hexane/ethyl acetate, 6:1) afforded the product (42 mg, 52%) as a light
yellow solid; mp 184–186 °C; Rf = 0.28 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz,
CDCl3) δ 8.54 (d, J = 1.3 Hz, 1H), 8.14 (dd, J1 = 1.7 Hz, J2 = 8.6 Hz, 1H), 8.07 (d, J = 8.0
Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.60-7.43 (m, 6H), 7.38-7.29 (m, 7H); 13C NMR (75
MHz, CDCl3) δ168.8, 154.3, 153.9, 143.2, 139.2, 136.6, 135.1, 130.0 (× 2), 129.8, 129.5 (×
2), 129.0, 128.9, 128.4 (× 2), 127.3 (× 2), 126.6, 126.2, 123.0, 122.9 (× 2), 121.5, 119.7,
111.0 cm−1; HRMS (ESI+) m/z 404.1249 (M+H+, C26H18N3S requires 404.1221).
2-(2-Phenethyl-1-phenyl-1H-benzoimidazol-5-yl)benzothiazole (71)
Compound 7 (64 mg, 0.2 mmol) and 3-phenylpropionaldehyde (26 mL, 0.2 mmol) were
used to synthesize 71 using the procedure described for preparation of 12. Flash column
chromatography (hexane/ethyl acetate, 3:1) afforded the product (41 mg, 48%) as a light
yellow solid; mp 56–58 °C; Rf = 0.10 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz,
CDCl3) δ 8.48 (s, 1H), 8.07 (dd, 2H, J1 = 3.2 Hz, J2 = 4.8 Hz), 7.91 (d, 1H, J = 7.9 Hz),
7.55-7.31 (m, 5H), 7.25-7.14 (m, 6H), 7.08 (d, 2H, J = 7.0 Hz), 3.21 (t, 4H, J = 6.5 Hz); 13C
NMR (75 MHz, CDCl3) δ 168.9, 156.0, 154.3, 142.8, 140.6, 138.4, 135.3, 135.1, 130.0 (×
2), 129.3, 128.5 (× 2), 128.4 (× 2), 127.3 (× 2), 126.3, 126.2, 124.9, 123.0 (× 2), 122.4,
121.5, 119.1, 110.6, 34.0, 29.8; IR (film) ν max 3052, 3028, 2921, 2862, 1596, 1514, 1498,
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1462, 1434, 1393, 1314, 1274, 758, 728, 699 cm−1; HRMS (ESI+) m/z 432.1542 (M+H+,
C28H22N3S requires 432.1534).
2-[2-((E)-2-Furan-2-yl-ethenyl)-1-phenyl-1H-benzoimidazol-5-yl]benzothiazole (69)
To a solution of compound 7 (64 mg, 0.2 mmol) and trans-3-(2-furyl)acrolein (24 mg, 0.2
mmol) in ethanol (15 mL) was added ZrCl4 (24 mg, 0.1 mmol). The reaction was heated to
80 °C and refluxed for 30 min. The reaction was cooled and poured into aqueous ammonium
hydroxide (5%, 50 mL). The product was extracted with CH2Cl2 (50 mL × 2). The organic
layers were combined, dried over anhydrous Na2SO4, and concentrated in vacuo. Flash
column chromatography (hexane/ethyl acetate, 5:1) afforded the product (69 mg, 82%) as a
yellow solid; mp 97–99 °C; Rf = 0.18 (hexane/ethyl acetate, 3:1); 1H NMR (400 MHz,
CDCl3) δ 8.47 (d, 1H, J = 1.1 Hz), 8.11 (dd, 1H, J1 = 1.5 Hz, J2 = 8.5 Hz), 8.07 (d, 1H, J =
7.9 Hz), 7.91 (d, 1H, J = 7.8 Hz), 7.83 (d, 1H, J = 15.7 Hz), 7.68-7.58 (m, 3H), 7.50-7.46
(m, 3H), 7.40-7.37 (m, 2H), 7.26 (d, 1H, J = 8.5 Hz), 6.71 (d, 1H, J = 15.7 Hz), 6.57 (d, 1H,
J = 3.3 Hz), 6.45 (dd, 1H, J1 = 1.8 Hz, J2 = 3.3 Hz); 13C NMR (100 MHz, CDCl3) δ 168.7,
154.3, 152.3, 152.0, 144.2, 138.4, 135.2, 134.9, 130.3 (× 2), 130.1, 129.5, 127.7 (× 2),
127.4, 125.7, 123.1, 123.0, 122.9 (× 2), 118.8, 118.7, 113.5, 112.5, 112.3, 110.9, 110.7; IR
(film) ν max 3284, 3060, 2931, 2860, 1652, 1608, 1595, 1498, 1434, 1380, 1314, 1273,
1224, 1016, 757, 695 cm−1; HRMS (ESI+) m/z 420.1166 (M+H+, C26H18N3OS requires
420.1171).
2-(1-Phenyl-2(E)-styryl-1H-benzoimidazol-5-yl)benzothiazole (70)
Compound 7 (64 mg, 0.2 mmol) and trans-cinnamaldehyde (26 mL, 0.2 mmol) were used to
synthesize 70 using the procedure described for preparation of 69. Flash column
chromatography (hexane/ethyl acetate, 5:1) afforded the product (73 mg, 85%) as a yellow
solid; mp 218–220 °C; Rf = 0.20 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ
8.48 (d, 1H, J = 1.4 Hz), 8.11 (dd, 1H, J1 = 1.6 Hz, J2 = 8.5 Hz), 8.07 (d, 1H, J = 8.1 Hz),
8.01 (d, 1H, J = 16.0 Hz), 7.90 (d, 1H, J = 7.6 Hz), 7.66-7.55 (m, 3H), 7.50-7.45 (m, 5H),
7.37-7.32 (m, 5H), 6.85 (d, 1H, J = 16.0 Hz); 13C NMR (75 MHz, CDCl3) δ 168.8, 154.3,
152.4, 143.4, 138.5, 138.1, 135.8, 130.14 (× 2), 129.3 (× 2), 129.2 (× 2), 128.8 (× 2), 127.4,
126.6 (× 2), 126.2, 123.0 (× 2), 122.7, 121.5, 119.2 (× 2), 113.5, 110.7 (× 2); IR (film) ν
max 3059, 2217, 1633, 1596, 1499, 1433, 1386, 1340,1274, 1216, 909, 756, 729 cm−1;
HRMS (ESI+) m/z 430.1393 (M+H+, C28H20N3S requires 430.1378).
2-{2-[(E)-2-(4-Methoxyphenyl)ethenyl]-1-phenyl-1H-benzoimidazol-5-yl} benzothiazole (72)
Compound 7 (64 mg, 0.2 mmol) and trans-4-methoxycinnamaldehyde (33 mg, 0.2 mmol)
were used to synthesize 72 using the procedure described for preparation of 69. Flash
column chromatography (hexane/ethyl acetate, 5:1) afforded the product (79 mg, 86%) as a
yellow solid; mp 177–179 °C; Rf = 0.17 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz,
CDCl3) δ 8.46 (d, 1H, J = 1.4 Hz), 8.10 (dd, 1H, J1 = 1.6 Hz, J2 = 8.6 Hz), 8.07 (d, 1H, J =
7.2 Hz), 7.98 (d, 1H, J = 16.0 Hz), 7.91 (d, 1H, J = 7.9 Hz), 7.66-7.59 (m, 3H), 7.49-7.34
(m, 6H), 7.25 (d, 1H, J = 8.5 Hz), 6.88 (d, 2H, J = 8.7 Hz), 6.69 (d, 1H, J = 16.0 Hz), 3.81
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.9, 160.6, 154.3, 152.9, 143.3, 138.5, 137.9,
135.2, 135.1, 130.2 (× 2), 129.3, 129.1 (× 2), 129.0, 128.6 (× 2), 127.5, 126.2, 124.9, 123.0,
122.5, 121.5, 118.9, 114.3 (× 2), 111.0, 110.5, 55.3; IR (film) ν max 3061, 2954, 2929,
2837, 1603, 1514, 1500, 1434, 1304, 1254, 1173, 759 cm−1; HRMS (ESI+) m/z 460.1473
(M+H+, C29H22N3OS requires 460.1484).
2-(2-Nona-1(E),3(E)-dienyl-1-phenyl-1H-benzoimidazol-5-yl)benzothiazole (73)
Compound 7 (64 mg, 0.2 mmol) and trans,trans-2,4-decadienal (35 mL, 0.2 mmol) were
used to synthesize 73 using the procedure described for preparation of 69. Flash column
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chromatography (hexane/ethyl acetate, 8:1) afforded the product (63 mg, 67%) as a yellow
glassy solid; Rf = 0.40 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 8.43 (d, J
= 1.5 Hz, 1H), 8.07 (m, 2H), 7.89 (d, J = 7.9 Hz, 1H), 7.64-7.56 (m, 4H), 7.50-7.33 (m, 4H),
7.23 (d, J = 19.0 Hz, 1H), 6.24-6.04 (m, 3H), 2.18-2.11 (m, 2H), 1.47-1.23 (m, 6H), 0.88 (t,
J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 168.9, 154.4, 152.9, 143.5, 142.0, 139.1,
138.5, 135.3, 135.1, 130.0 (× 2), 129.5, 129.2, 129.0 (× 2), 127.5, 126.2, 124.8, 123.0,
122.4, 121.5, 119.0, 114.4, 110.4, 33.0, 31.4, 28.6, 22.5, 14.0; IR (film) ν max 3048, 2925,
2855, 1638, 1614, 1596, 1498, 1455, 1434, 1388, 1314, 1291, 993, 757 cm−1; HRMS (ESI
+) m/z 450.2025 (M+H+, C29H28N3S requires 450.2004).
2-(1-Phenyl-1H-benzoimidazol-5-yl)benzothiazole (74)
To a solution of 7 (130 mg, 0.4 mmol) and 10 (65 mg, 0.4 mmol) in anhydrous ethanol (15
mL) was added activated 3Å molecular sieves (0.5 g). The reaction was heated to 80 °C and
refluxed for 48 h. The reaction was cooled and filtered through a fritted funnel. The
molecular sieves were washed with ethanol (10 mL), and the combined filtrate was
concentrated in vacuo. Flash column chromatography (hexane/ethyl acetate, 2:1) afforded
the product (20 mg, 31%) as a white solid; mp 138–140 °C; Rf = 0.17 (hexane/ethyl acetate,
1:1); 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 1.1 Hz, 1H), 8.15 (s, 1H), 8.14 (dd, J1 = 1.4
Hz, J2 = 9.9 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.58-7.54 (m, 3H),
7.49-7.44 (m, 4H), 7.34 (t, J = 7.3 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 168.4, 154.2,
144.3, 143.7, 135.8, 135.5, 135.0, 130.2 (× 2), 128.8, 128.4, 126.9, 126.2, 124.9, 124.0 (×
2), 123.2, 123.0, 121.5, 120.3, 111.0; IR (film) ν max 3382, 3064, 2954, 2360, 1617, 1599,
1509, 1461, 1435, 1314, 1284, 1240, 1216, 1167, 750, 719, 692 cm−1; HRMS (ESI+) m/z
328.0897 (M+H+, C20H14N3S requires 328.0908).
3-(5-Benzothiazol-2-yl-1-phenyl-1H-benzoimidazol-2-yl)chromen-2-one (75)
To coumarin-3-carboxylic acid (40 mg, 0.2 mmol) in a round bottom flask (25 mL) fitted
with a condenser was added thionyl chloride (2 mL, 10 mmol). The reaction was heated to
80 °C and refluxed for 2 h. Excess thionyl chloride was removed by distillation, and the
residue was further dried by applying high vacuum for 30 min. The residue was dissolved in
anhydrous toluene (5 mL), compound 7 (64 mg, 0.2 mmol) was added, and the reaction was
stirred at 22 °C for 30 min. The reaction was subsequently heated to 110 °C and refluxed for
12 h. The reaction was cooled and concentrated in vacuo. Flash column chromatography
(hexane/ethyl acetate, 5:1) afforded the product (36 mg, 38%) as a off white solid; mp 164–
166 °C; Rf = 0.20 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 8.57 (d, J = 1.4
Hz, 1H), 8.40 (s, 1H), 8.21 (dd, J1 = 1.6 Hz, J2 = 8.5 Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.94
(d, J = 7.9 Hz, 1H), 7.64-7.35 (m, 12H); 13C NMR (75 MHz, CDCl3) δ 168.5, 157.8, 154.5,
154.3, 149.0, 146.4, 142.9, 138.6, 136.1, 135.1, 133.1, 129.8 (× 2), 129.2, 128.9, 128.8,
126.2 (× 2), 126.1,125.0, 124.9, 123.7, 124.9, 123.7, 123.0, 121.6, 119.9, 119.3, 118.5,
116.8, 111.2; IR (film) ν max 3060, 2966, 1735, 1608, 1499, 1456, 1434, 1386, 1325, 1282,
1242, 1215, 756 cm−1; HRMS (ESI+) m/z 472.1113 (M+H+, C29H18N3O2S requires
472.1120).
5-Benzothiazol-2-yl-3-ethyl-1,2-diphenyl-3H-benzoimidazol-1-ium, iodide (19)
Compound 68 (30 mg, 0.074 mmol) and ethyl iodide (3 mL) were used to synthesize 19
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (37 mg, 90%) as a white solid; mp 72–74 °C; Rf = 0.33
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.88 (s, 1H), 8.43 (d, J = 8.6 Hz,
1H), 8.09 (t, J = 8.2 Hz, 2H), 7.73-7.47 (m, 13H), 4.65 (q, J = 7.1 Hz, 2H), 1.64 (t, J = 7.1
Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 166.6, 154.1, 152.5, 135.6, 135.0, 133.4, 133.3,
132.9, 132.0, 131.2, 130.7 (× 2), 130.5 (× 2), 129.7 (× 2), 127.7 (× 2), 127.4, 127.1, 126.3,
123.3, 122.2, 121.4, 114.6, 112.2, 42.6, 14.0; IR (film) ν max 3425, 3060, 2990, 1778, 1737,
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1688, 1502, 1454, 1434, 1198, 1151, 1138, 760, 703 cm−1; HRMS (ESI+) m/z 432.1518
(M+, C28H22N3S requires 432.1534).
5-Benzothiazol-2-yl-3-ethyl-2-phenethyl-1-phenyl-3H-benzoimidazol-1-ium, iodide (22)
Compound 71 (35 mg, 0.08 mmol) and ethyl iodide (3 mL) were used to synthesize 22 using
the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (44 mg, 93%) as a white solid; mp 131–133 °C; Rf = 0.30
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.73 (s, 1H), 8.30 (dd, J1 = 1.4
Hz, J2 = 8.6 Hz, 1H), 8.04 (t, J = 8.1 Hz, 2H), 7.83-7.72 (m, 3H), 7.58-7.44 (m, 5H),
7.24-7.21 (m, 3H), 6.99-6.96 (m, 2H), 4.70 (q, J = 7.2 Hz, 2H), 3.52 (t, J = 7.6 Hz, 2H), 2.98
(t, J = 7.6 Hz, 2H), 1.65 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 167.5, 155.8,
155.0, 139.4, 136.6, 135.8, 133.9, 133.2, 132.9, 132.5, 132.0 (× 2), 130.2 (× 2), 129.4 (× 2),
128.5 (× 2), 128.4, 128.1, 128.0, 127.2, 124.2, 123.1, 115.1, 112.8, 42.9, 33.8, 27.8, 14.9; IR
(film) ν max 3416, 3064, 1733, 1688, 1506, 1471, 1455, 1199, 1135, 762, 701 cm−1; HRMS
(ESI+) m/z 460.1833 (M+, C30H26N3S requires 460.1847).
5-Benzothiazol-2-yl-3-ethyl-2-((E)-2-furan-2-yl-ethenyl)-1-phenyl-3H-benzo imidazol-1-ium,
iodide (20)
Compound 69 (30 mg, 0.07 mmol) and ethyl iodide (3 mL) were used to synthesize 20 using
the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (35 mg, 88%) as a yellow solid; mp 83–85 °C; Rf = 0.30
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.60 (d, 1H, J = 1.0 Hz), 8.19 (dd,
J1 = 1.5 Hz, J2 = 8.7 Hz, 1H), 7.95 (t, J = 7.3 Hz, 2H), 7.72-7.62 (m, 6H), 7.47-7.35 (m,
3H), 6.85 (d, J = 1.4 Hz, 2H), 6.73 (d, J = 3.5 Hz, 1H), 6.51 (q, J = 1.8 Hz, 1H), 4.73 (q, J =
7.3 Hz, 2H), 1.61 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 168.0, 155.5, 152.0,
150.4, 149.0, 136.9, 136.8, 134.8, 134.7, 134.3, 133.6, 133.4, 132.7, 131.8, 129.2 (× 2),
128.5 (× 2), 127.6, 120.2, 115.1, 114.9, 112.7, 104.4, 43.2, 15.2; IR (film) ν max 3429,
3063, 2342, 1688, 1626, 1447, 1199, 1128, 762 cm−1; HRMS (ESI+) m/z 448.1454 (M+,
C28H22N3OS requires 448.1484).
5-Benzothiazol-2-yl-3-ethyl-1-phenyl-2(E)-styryl-3H-benzoimidazol-1-ium, iodide (21)
Compound 70 (35 mg, 0.08 mmol) and ethyl iodide (3 mL) were used to synthesize 21 using
the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (43 mg, 92%) as a light yellow solid; mp 199–202 °C; Rf
= 0.33 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.76 (d, J = 0.9 Hz, 1H),
8.34 (dd, J1 = 1.5 Hz, J2 = 8.7 Hz, 1H), 8.06 (t, J = 7.7 Hz, 2H), 7.82-7.76 (m, 6H),
7.57-7.42 (m, 9H), 7.21 (q, J = 7.2 Hz, 2H), 1.73 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz,
MeOH-d4) δ 166.6, 154.1, 149.5, 148.9, 135.6, 135.4, 134.1, 133.6, 133.0, 132.1, 132.0,
131.8, 131.2 (× 2), 129.4 (× 2), 128.5 (× 2), 127.8 (× 2), 127.2, 127.1, 126.3, 123.3, 122.2,
114.0, 111.6, 106.6, 42.0, 13.9; IR (film) ν max 3416, 3061, 2988, 1688, 1632, 1503, 1470,




Compound 72 (35 mg, 0.076 mmol) and ethyl iodide (3 mL) were used to synthesize 23
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (42 mg, 90%) as a yellow solid; mp 188–192 °C; Rf =
0.33 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.51 (d, J = 1.0 Hz, 1H),
8.09 (d, J = 1.4 Hz, 1H), 7.88 (t, J = 7.5 Hz, 1H), 7.68-7.66 (m, 5H), 7.60-7.33 (m, 5H), 6.90
(d, J = 3.1 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.67 (q, J = 7.2 Hz, 2H), 3.68 (s, 3H), 1.55(t, J
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= 7.2 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 170.4, 167.2, 157.8, 153.4, 152.3, 139.2,
139.0, 137.4, 136.4, 135.7, 135.5, 135.0 (× 2), 134.4 (× 2), 131.6 (× 2), 130.9, 130.8, 130.7,
130.0 126.9, 125.9, 118.5 (× 2), 117.4, 115.0, 107.0, 58.8, 46.2, 17.6; IR (film) ν max 3404,
3064, 1688, 1628, 1599, 1573, 1520, 1470, 1256, 1199, 1176, 1116, 763 cm−1; HRMS (ESI
+) m/z 488.1770 (M+, C31H26N3OS requires 488.1797).
5-Benzothiazol-2-yl-3-ethyl-2-nona-1(E),3(E)-dienyl-1-phenyl-3H-benzoimidazol-1-ium,
iodide (24)
Compound 73 (30 mg, 0.067 mmol) and ethyl iodide (3 mL) were used to synthesize 24
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (36 mg, 89%) as a yellow solid; mp 66–68 °C; Rf = 0.33
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.68 (d, J = 1.0 Hz, 1H), 8.26 (dd,
J1 = 1.5 Hz, J2 = 8.7 Hz, 1H), 8.04 (t, J = 6.4 Hz, 2H), 7.81-7.30 (m, 9H), 6.73-6.62 (m,
1H), 6.42-6.34 (m, 1H), 6.11-6.01 (m, 1H), 4.73 (q, J = 7.2 Hz, 2H), 2.22-2.16 (m, 2H), 1.65
(t, J = 7.2 Hz, 3H), 1.44-1.29 (m, 6H), 0.89 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, MeOH-
d4) δ 166.7, 154.1, 149.6, 149.4, 135.6, 135.4, 134.0, 133.5, 132.8, 132.0, 131.9, 131.2 (× 2),
129.6, 127.8 (× 2), 127.1, 127.0, 126.2, 123.2, 122.2, 113.7, 111.3, 107.4, 41.7, 33.2, 31.5,
28.3, 22.5, 13.8, 13.6; IR (film) ν max 3416, 3051, 2950, 2923, 2862, 1687, 1632, 1613,
1501, 1469, 1198, 1166, 1126, 762 cm−1; HRMS (ESI+) m/z 478.2298 (M+, C31H32N3S
requires 478.2317).
5-Benzothiazol-2-yl-3-ethyl-1-phenyl-3H-benzoimidazol-1-ium, iodide (13)
Compound 74 (35 mg, 0.11 mmol) and ethyl iodide (3 mL) were used to synthesize 13 using
the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (49 mg, 93%) as a white solid; mp 122–124 °C; Rf = 0.30
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 9.95 (s, 1H), 8.71 (d, J = 1.0 Hz,
1H), 8.34 (dd, J1 = 1.5 Hz, J2 = 8.8 Hz, 1H), 7.98 (t, J = 7.1 Hz, 2H), 7.87 (d, J = 8.8 Hz,
1H), 7.76-7.68 (m, 5H), 7.49-7.32 (m, 2H), 4.70 (q, J = 7.3 Hz, 2H), 1.72 (t, J = 7.3 Hz,
3H); 13C NMR (75 MHz, MeOH-d4) δ 167.4, 155.1, 144.4, 136.6, 134.7, 134.5, 134.2,
133.5, 132.2, 131.8 (× 2), 128.3, 128.1, 127.3, 126.3 (× 2), 124.3, 123.1, 115.7, 113.4, 44.4,
14.5; IR (film) ν max 3434, 3131, 3064, 1780, 1736, 1686, 1561, 1499, 1478, 1446, 1416,




Compound 75 (20 mg, 0.042 mmol) and ethyl iodide (3 mL) were used to synthesize 25
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (21 mg, 81%) as a light yellow solid; mp 206–208 °C; Rf
= 0.25 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, DMSO-d6) δ 8.88 (d, J = 1.0 Hz, 1H),
8.63 (s, 1H), 8.43 (dd, J1 = 1.5 Hz, J2 = 8.8 Hz, 1H), 8.06 (dd, J1 = 1.0 Hz, J2 = 8.1 Hz, 2H),
7.78-7.38 (m, 12H), 4.76 (q, J = 7.2 Hz, 2H), 1.60 (t, J = 7.2 Hz, 3H); 13C NMR (75 MHz,
DMSO-d6) δ 166.7, 158.2, 155.8, 154.7, 153.5, 147.2, 136.7, 136.2, 135.5, 134.1, 133.0,
132.5, 132.4, 131.4 (× 2), 131.3, 128.4, 128.0 (× 2), 127.9, 127.0, 123.1, 118.3, 117.8,
115.6, 113.3, 110.8, 43.7, 15.0; IR (film) ν max 3412, 3060, 1725, 1687, 1609, 1576, 1503,
1437, 1255, 1201, 1174, 1128, 761 cm−1; HRMS (ESI+) m/z 500.1440 (M+, C31H22N3O2S
requires 500.1433).
(4-Benzothiazol-2-yl-2-nitrophenyl)cyclohexylamine (44)
To a solution of 4 (580 mg, 2.0 mmol) in DMSO (5 mL) was added cyclohexylamine (1.16
mL, 10.0 mmol). The reaction was stirred at 22 °C for 48 h. The reaction was poured into
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aqueous HCl (1.0 M, 50 mL), and the product was extracted with diethyl ether (50 mL × 3).
The combined organic phase was washed with saturated aqueous NaCl (100 mL), dried over
anhydrous Na2SO4, and concentrated in vacuo. Column chromatography (CH2Cl2) afforded
the product (609 mg, 87%) as a orange solid, mp 138–140 °C; Rf = 0.47 (hexane/ethyl
acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 8.78 (s, 1H), 8.28 (d, J = 7.2 Hz,, 1H), 8.13 (d,
J = 9.0 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.45 (dd, J1 = 7.4 Hz, J2
= 7.9 Hz, 1H), 7.36 (dd, J1 = 7.6 Hz, J2 = 7.6 Hz, 1H), 6.92 (d, J = 9.1 Hz, 1H), 3.56 (m,
1H), 2.05 (m, 2H), 1.81 (m, 2H), 1.69-1.21 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 166.1,
154.0, 145.8, 135.1, 134.6, 134.3, 131.2, 126.5, 126.3, 124.9, 122.7, 121.5, 120.8, 114.7,
51.3, 32.6 (× 2), 25.5, 24.5 (× 2); IR (film) ν max 3556, 2931, 2854, 1624, 1567, 1534,
1488, 1436, 1361, 1266, 1217, 1155, 757 cm−1; HRMS (ESI+) m/z 354.1280 (M+H+,
C19H20N3O2S requires 354.1276).
(4-Benzothiazol-2-yl-2-nitrophenyl)hexylamine (45)
Compound 4 (580 mg, 2.0 mmol) and n-hexylamine (1.3 mL, 10.0 mmol) were used to
synthesize 45 using the procedure described for preparation of the synthesis of 44. The
reaction was stirred at 22 °C for 48 h. The reaction was poured into aqueous HCl (1.0 M, 50
mL), and the product was extracted with diethyl ether (50 mL × 3). The combined organic
phase was washed with saturated aqueous NaCl (100 mL), dried over anhydrous Na2SO4,
and concentrated in vacuo. The residue was purified by column chromatography on silica
gel with CH2Cl2 to afford the product (625 mg, 88%) as a orange solid, mp 98–100 °C; Rf =
0.50 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 8.78 (t, J = 2.0 Hz, 1H),
8.28 (s, br, 1H), 8.15 (d, J = 6.9 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H),
7.45 (dd, J1 = 7.2 Hz, J2 = 8.1 Hz, 1H), 7.34 (dd, J1 = 7.3 Hz, J2 = 7.8 Hz, 1H), 6.89 (dd, J1
= 2.4 Hz, J2 = 9.1 Hz, 1H), 3.31 (m, 2H), 1.73 (m, 2H), 1.45 (m, 2H), 1.35 (m, 4H), 0.91 (t,
J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 166.0, 154.0, 146.7, 134.6, 134.4, 131.3,
126.3, 126.2, 125.0, 122.8, 121.5, 121.1, 114.3, 43.3, 31.4, 28.8, 26.7, 22.5, 14.0; IR (film) ν
max 3372, 2955, 2931, 2858, 1626, 1566, 1488, 1360, 1269, 1214, 1159, 758 cm−1; HRMS
(ESI+) m/z 356.1413 (M+H+, C19H22N3O2S, requires 356.1433).
(4-Benzothiazol-2-yl-2-nitrophenyl)-(4-methoxyphenyl)amine (46)
Compound 4 (580 mg, 2.0 mmol) and p-anisidine (1.23 g, 10.0 mmol) was used to
synthesize 46 using the procedure described for preparation of the synthesis of 44. Column
chromatography (CH2Cl2) afforded the product (560 mg, 74%) as a orange solid, mp 188–
190 °C; Rf = 0.40 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz, CDCl3) δ 9.65 (s, 1H),
8.84 (s, 1H), 8.02 (m, 2H), 7.85 (d, J = 9.0 Hz, 1H), 7.48-6.96 (m, 7H), 3.85 (s, 3H); 13C
NMR (75 MHz, CDCl3) δ 165.7, 158.4, 154.0, 145.7, 134.7, 134.0, 132.1, 130.3, 127.2 (×
2), 126.4, 126.0, 125.1, 122.9, 122.7, 121.6, 116.3, 115.1 (× 2); IR (film) ν max 3337, 1626,
1593, 1568, 1510, 1486, 1352, 1247, 1208, 1147, 753 cm−1; HRMS (ESI+) m/z 378.0919
(M+H+, C20H16N3O3S requires 378.0912).
4-Benzothiazol-2-yl-N1-cyclohexylbenzene-1,2-diamine (51)
Compound 44 (354 mg, 1.0 mmol) was treated with anhydrous hydrazine (0.2 mL, 6.4
mmol) and Pd/C (10%, 106 mg, 0.1 mmol) using the procedure described for preparation of
7. Flash column chromatography (hexane/ethyl acetate, 8:1) afforded the product (291 mg,
90%) as a yellow solid, mp 168–170 °C; Rf = 0.37 (hexane/ethyl acetate, 1:1); 1H NMR
(300 MHz, CDCl3) δ 8.08 (d, J = 7.9 Hz,, 1H), 7.97 (d, J = 8.1 Hz, 1H), 7.51 (m, 2H), 7.42
(dd, J1 = 7.7 Hz, J2 = 7.7 Hz, 1H), 7.29 (dd, J1 = 7.6 Hz, J2 = 7.6 Hz, 1H), 6.65 (d, J = 8.7
Hz, 1H), 3.48 (br, 3H), 3.32 (m, 1H), 2.08 (m, 2H), 1.78 (m, 2H), 1.66 (m, 1H), 1.29 (m,
5H); 13C NMR (75 MHz, CDCl3) δ 169.1, 154.3, 140.6, 134.6, 133.1, 126.0, 124.2, 122.5,
121.9, 121.3, 115.9, 110.6, 51.4, 33.3 (× 2), 25.9, 24.9 (× 2); IR (film) ν max 3369, 3215,
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3050, 2930, 2862, 1604, 1462, 1431, 1300, 1256, 1147, 756 cm−1; HRMS (ESI+) m/z
324.1506 (M+H+, C19H22N3S requires 324.1534).
4-Benzothiazol-2-yl-N1-hexylbenzene-1,2-diamine (53)
Compound 45 (356 mg, 1.0 mmol) was treated with anhydrous hydrazine (0.2 mL, 6.4
mmol) and Pd/C (10%, 106 mg, 0.1 mmol) according to the procedure described for 7. Flash
column chromatography (hexane/ethyl acetate, 8:1) afforded the product (282 mg, 87%) as a
yellow solid, mp 151–153 °C; Rf = 0.40 (hexane/ethyl acetate, 3:1); 1H NMR (300 MHz,
CDCl3) δ 7.88 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.53 (m, 1H), 7.42 (dd, J1 = 7.3
Hz, J2 = 7.8 Hz, 1H), 7.29 (dd, J1 = 7.3 Hz, J2 = 7.8 Hz, 1H), 6.64 (d, J = 8.8 Hz, 1H), 3.77
(br, 1H) 3.38 (br, 2H), 3.14 (t, J =7.1 Hz, 2H), 1.65 (m, 2H), 1.39 (m, 2H), 1.32 (m, 4H),
0.90 (t, J = 6.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 169.0, 154.3, 141.7, 134.6, 133.2,
126.0, 124.3, 122.9, 122.3, 121.8, 121.4, 115.4, 110.2, 43.9, 31.6, 29.4, 26.9, 22.6, 14.0; IR
(film) ν max 3379.8, 3212.9, 3018.9, 2952.1, 2916.7, 2848.5, 1647.9, 1594.3, 1459.8,
1438.6, 1364.1, 1307.4, 1215.5, 1160.7 769.8, 753.6, 726.3 cm−1; HRMS (ESI+) m/z
326.1666 (M+H+, C19H24N3S, requires 326.1691).
4-Benzothiazol-2-yl-N1-cyclohexylbenzene-1,2-diamine (53)
Compound 46 (378 mg, 1.0 mmol) was treated with anhydrous hydrazine (0.2 mL, 6.4
mmol) and Pd/C (10%, 106 mg, 0.1 mmol) using the procedure described for preparation of
7. Flash column chromatography (hexane/ethyl acetate, 6:1) afforded the product (295 mg,
85%) as a yellow solid, mp 155–157 °C; Rf = 0.33 (hexane/ethyl acetate, 1:1); 1H NMR
(300 MHz, CDCl3) δ 8.01 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 1.9 Hz,
1H), 7.47-7.30 (m, 3H), 7.04 (d, J = 8.2 Hz, 1H), 6.95 (d, J = 8.9 Hz, 1H), 6.86 (d, J = 8.9
Hz, 1H), 5.40 (s, 1H), 3.79 (s, 3H), 3.68 (br, 2H); 13C NMR (75 MHz, CDCl3) δ 168.4,
155.1, 154.2, 137.3, 136.2, 135.7, 134.8, 127.1, 126.1, 124.6, 122.6, 121.5, 121.0 (× 2),
120.2, 117.3, 115.3, 114.8 (× 2), 55.6; IR (film) ν max 3361, 3260, 3058, 3003, 2953, 2833,
1600, 1509, 1477, 1437, 1311, 1243, 1034, 822, 758 cm−1; HRMS (ESI+) m/z 348.1156 (M
+H+, C20H18N3OS requires 348.1156).
[(E)-2-(5-Benzothiazol-2-yl-1-cyclohexyl-1H-benzoimidazol-2-yl)ethenyl]
methylphenylamine (65)
Compound 51 (65 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24 mg, 0.1 mmol)
were used to synthesize 65 using the procedure described for preparation of 12. Flash
column chromatography (hexane/ethyl acetate, 6:1) afforded the product (64 mg, 69%) as a
yellow solid; mp 114–116 °C; Rf = 0.53 (hexane/ethyl acetate, 1:1); 1H NMR (300 MHz,
CDCl3) δ 8.30 (d, J = 13.1 Hz,, 1H), 8.25 (d, J = 1.5 Hz,, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.95
(dd, J1 = 8.1 Hz, J2 = 1.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.51 (d, J = 8.2 Hz, 1H), 7.45
(dd, J1 = J2 = 7.7 Hz, 1H), 7.36-7.20 (m, 5H), 7.06 (t, J = 7.3 Hz, 1H), 5.46 (d, J = 13.2 Hz,
1H), 4.26 (m, 1H), 3.39 (s, 3H), 2.25 (m, 2H), 2.02 (m, 4H), 1.84 (m, 1H), 1.45 (m, 3H); 13C
NMR (75 MHz, CDCl3) δ 169.6, 155.1, 154.4, 146.8, 144.2, 143.1, 136.5, 135.1, 129.4 (×
2), 127.2, 126.0, 124.6, 123.4, 122.8, 121.5, 119.8, 119.5 (× 2), 117.6, 111.2, 87.0, 56.0,
36.4, 30.1 (× 2), 26.2 (× 2), 25.4; IR (film) ν max 3060, 2931, 2849, 1625, 1593, 1490,
1466, 1436, 1301, 1127, 755 cm−1; HRMS (ESI+) m/z 465.2129 (M+H+, C29H29N4S
requires 465.2113).
[(E)-2-(5-Benzothiazol-2-yl-1-hexyl-1H-benzoimidazol-2-yl)ethenyl]methyl phenylamine (66)
Compound 52 (65 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24 mg, 0.1 mmol)
were used to synthesize 66 using the procedure described for preparation of 12. Flash
column chromatography (hexane/ethyl acetate, 6:1) afforded the product (66 mg, 71%) as a
yellow solid; mp 60–62 °C; Rf = 0.53 (hexane/ethyl acetate, 1:1); 1H NMR (300 MHz,
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CDCl3) δ 8.34 (d, J = 13.1 Hz, 1H), 8.24 (d, J = 1.5 Hz, 1H), 8.03 (m, 2H) 7.87 (d, J = 7.9
Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.38-7.23 (m, 6H), 7.09 (t, J = 8.2 Hz, 1H), 5.36 (d, J =
13.1 Hz, 1H), 4.10 (t, J = 7.1 Hz, 2H) 3.37 (s, 3H), 1.82 (m, 2H), 1.33 (m, 6H), 0.90 (t, J =
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 169.7, 155.2, 154.4, 146.7, 143.7, 142.9, 137.8,
135.1, 129.4 (× 2), 127.6, 126.0, 124.6, 123.5, 122.8, 121.5, 120.2, 119.5 (× 2), 117.4,
108.7, 86.3, 43.3, 36.4, 31.4, 29.8, 22.5, 14.0; IR (film) ν max 3059, 2953, 2928, 2856,
1628, 1593, 1491, 1467, 1437, 1325, 1302, 1265, 1127, 756 cm−1; HRMS (ESI+) m/z
467.2257 (M+H+, C29H31N4S requires 467.2269).
{(E)-2-[5-Benzothiazol-2-yl-1-(4-methoxyphenyl)-1H-benzoimidazol-2-
yl]ethenyl}methylphenylamine (67)
Compound 53 (70 mg, 0.2 mmol), 10 (32 mg, 0.2 mmol), and ZrCl4 (24 mg, 0.1 mmol)
were used to synthesize 67 using the procedure described for preparation of 12. Flash
column chromatography (hexane/ethyl acetate, 5:1) afforded the product (70 mg, 72%) as a
yellow solid; mp 182–184 °C; Rf = 0.53 (hexane/ethyl acetate, 1:1); 1H NMR (300 MHz,
CDCl3) δ 8.31-8.27 (m, 2H), 8.04 (d, J = 8.2 Hz,, 1H), 7.96 (dd, J1 = 8.3 Hz, J2 = 1.6 Hz,
1H), 7.87 (d, J = 7.9 Hz, 1H), 7.45-7.30 (m, 6H), 7.17-6.92 (m, 6H), 5.18 (d, J = 13.3 Hz,
1H), 3.90 (s, 3H), 3.16 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 169.5, 159.7, 155.9, 154.4,
146.6, 143.8, 142.4, 139.2, 135.1, 129.3 (× 2), 128.8 (× 2), 128.3, 128.1, 126.0, 124.6,
123.4, 122.8, 121.5, 120.7, 119.2 (× 2), 117.7, 115.1 (× 2), 109.5, 87.3, 55.6, 36.0; IR (film)
ν max 3060, 2007, 2934, 2836, 1627, 1592, 1514, 1491, 1465, 1435, 1296, 1251, 1127, 755
cm−1; HRMS (ESI+) m/z 489.1754 (M+H+, C30H25N4OS requires 489.1749).
5-Benzothiazol-2-yl-1-cyclohexyl-3-ethyl-2-[(E)-2-
(methylphenylamino)ethenyl]-3Hbenzoimidazol-1-ium, iodide (26)
Compound 65 (30 mg, 0.065 mmol) and ethyl iodide (3 mL) were used to synthesize 26
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (36 mg, 90%) as a yellow solid; mp 112–114 °C; Rf =
0.28 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.40 (s, 1H), 8.11 (m, 2H),
7.98 (m, 2H), 7.66 (dd, J1 = 7.3 Hz, J2 = 6.3 Hz, 1H), 7.52-7.31 (m, 6H), 7.23 (dd, J1 = J2 =
7.3 Hz, 1H), 5.50 (d, J = 13.5 Hz, 1H), 4.63 (m, 1H), 4.49 (q, J = 7.2 Hz, 2H), 3.53 (s, 3H),
2.35 (m, 2H), 2.02 (m, 4H), 1.78 (m 1H), 1.54 (t, J = 7.2 Hz, 3H), 1.56-1.37 (m, 3H); 13C
NMR (75 MHz, MeOH-d4) δ 168.6, 155.5, 154.4, 154.3 (× 2), 151.3 (× 2), 148.0, 136.8,
134.5, 134.0, 132.3, 131.4 (× 2), 128.4, 127.5, 126.3, 124.4, 123.5, 122.4, 116.8, 111.9,
79.4, 61.6, 43.1, 38.3, 32.0 (× 2), 27.3 (× 2), 26.3, 14.8; IR (film) ν max 3342 (br), 3060,
2931, 2948, 1688, 1616, 1588, 1528, 1494, 1461, 1363, 1305, 1199, 1172, 1130, 761 cm−1;
HRMS (ESI+) m/z 493.2415 (M+, C31H33N4S requires 493.2426).
5-Benzothiazol-2-yl-3-ethyl-1-hexyl-2-[(E)-2-(methylphenylamino)ethenyl]-3H-
benzoimidazol-1-ium, iodide (27)
Compound 66 (30 mg, 0.064 mmol) and ethyl iodide (3 mL) were used to synthesize 27
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (36 mg, 91%) as a yellow solid; mp 128–131 °C; Rf =
0.25 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.33 (d, J = 1.1 Hz, 1H),
8.13 (m, 1H), 7.98 (m, 2H), 7.80 (m, 2H), 7.49-7.17 (m, 7H), 5.45 (d, J = 13.2 Hz, 1H), 4.50
(q, J = 7.3 Hz, 2H) 4.32 (t, J = 7.7 Hz, 2H), 3.53 (s, 3H), 1.87 (m, 2H), 1.53 (t, J = 7.2 Hz,
1H) 1.33 (m, 2H), 1.27 (m, 4H), 0.83 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ
168.7, 155.5, 153.5, 151.4, 136.8, 135.6, 133.8, 132.5, 131.5 (× 3), 128.4, 127.9, 127.4,
126.7, 124.4, 123.5, 122.9, 122.8, 113.9, 111.4, 79.8, 47.5, 42.7, 32.9 (× 2), 30.2, 27.8, 24.0,
14.7, 14.6; IR (film) ν max 3412.8, 3060.3, 2942.7, 2919.2, 2860.5, 1689.5, 1620.5, 1587.7,
1535.6, 1493.0, 1357.9, 1199.8, 1130.2, 760.2 cm−1; HRMS (ESI+) m/z 495.2572 (M+,
C31H35N4S requires 495.2582).
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Compound 67 (35 mg, 0.072 mmol) and ethyl iodide (3 mL) were used to synthesize 28
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 20:1) afforded the product (42 mg, 92%) as a yellow solid; mp 174-176 °C; Rf =
0.22 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.34 (s, 1H), 7.92 (m, 2H),
7.48 (d, J = 8.8 Hz, 2H), 7.41-7.03 (m, 9H), 6.70 (d, J = 7.5 Hz, 2H), 5.36 (d, J = 14.0 Hz,
1H), 4.47 (q, J = 6.9 Hz, 2H), 3.85 (s, 3H), 3.30 (s, 3H), 1.49 (t, J = 7.1 Hz, 3H); 13C NMR
(75 MHz, MeOH-d4) δ 168.6, 163.7, 155.5, 153.5, 151.9, 147.6, 137.6, 136.7, 133.3, 132.4,
131.1 (× 2), 130.8 (× 2), 128.4, 127.8, 127.4, 124.4, 123.5, 121.8, 118.3 (× 2), 113.4, 110.9,
79.8, 57.0, 41.7, 37.3, 14.4; IR (film) ν max 3412 (br), 3050, 2932, 2840, 1682, 1613, 1588,




Compound 12 (30 mg, 0.066 mmol) and (2-iodoethyl)benzene (3 mL) were used to
synthesize 29 using the procedure described for preparation of 1. Flash column
chromatography (CH2Cl2/MeOH, 30:1) afford the product (43 mg, 87%) as a yellow solid;
mp 83–85 °C; Rf = 0.41 (CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.31 (d, J
= 1.3 Hz, 1H), 8.18-8.03 (m, 3H), 7.78-7.75 (m, 3H), 7.62-7.42 (m, 4H), 7.31-7.02 (m, 9H),
6.83 (d, J = 13.5 Hz, 1H), 6.65 (br, 2H), 5.03-4.84 (m, 5H), 4.52 (m, 2H), 3.23 (s, 3H); 13C
NMR (75 MHz, MeOH-d4) δ 168.5, 155.5, 154.1, 151.4, 139.2, 136.9, 136.8, 136.3, 133.5,
133.3 (× 2), 132.9, 132.7, 131.1(× 2), 130.9 (× 2), 130.4 (× 2), 129.4 (× 2), 128.9, 128.4,
127.7, 127. 4, 126.9, 124.4, 123.5, 121.6, 113.4, 111.6, 79.8, 48.0, 37.0, 35.9; IR (film) ν
max 3428, 3061, 2943, 2860, 1689, 1616, 1586, 1535, 1494, 1464, 1370, 1307, 1200, 1167,




Compound 12 (35 mg, 0.076 mmol) and 1-iodo-hexane (3 mL) were used to synthesize 30
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 30:1) afforded 30 (47 mg, 92%) as a yellow solid, mp 86–88 °C; Rf = 0.37 (CH2Cl2/
MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.40 (d, J = 1.1 Hz, 1H), 8.06-7.95 (m,
3H), 7.78-7.74 (m, 3H), 7.67-7.64 (m, 2H), 7.48-7.38 (m, 2H), 7.26 (m, 2H), 7.23-7.12 (m,
3H), 6.72 (br, 2H), 5.47 (d, J = 11.9 Hz, 1H), 4.50 (m, 2H), 3.36 (s, 3H), 1.95 (m, 2H), 1.51
(m, 2H), 1.36 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, MeOH-d4) δ 168.6,
155.5, 153.8, 152.1, 137.2, 136.7, 136.4, 134.0, 133.3 (× 2), 133.0, 132.6, 131.1 (× 2), 129.6
(× 2), 128.4, 127.4, 126.9, 124.4, 123.5, 121.9, 113.5, 111.2, 79.9, 46.5, 36.8, 33.0, 30.0,
27.9, 24.1, 14.8; IR (film) ν max 3331, 3060, 2943, 2931, 2849, 1688, 1617, 1586, 1537,
1494, 1464, 1369, 1310, 1120, 1167, 1127, 799, 761, 697 cm−1; HRMS (ESI+) m/z
543.2548 (M+, C35H35N4S requires 543.2582).
5-Benzothiazol-2-yl-3-dodecyl-2-[(E)-2-(methylphenylamino)ethenyl]-1-phenyl-3H-
benzoimidazol-1-ium, iodide (31)
Compound 12 (30 mg, 0.066 mmol) and 1-iodo-dodecane (3 mL) were used to synthesize 31
using the procedure described for preparation of 1. Flash column chromatography (CH2Cl2/
MeOH, 30:1) afforded the product (43 mg, 87%) as a yellow glassy solid; Rf = 0.44
(CH2Cl2/MeOH, 10:1); 1H NMR (300 MHz, MeOH-d4) δ 8.42 (s, 1H), 8.07-7.95 (m, 3H),
7.79-7.64 (m, 5H), 7.51-7.36 (m, 2H), 7.27-7.15 (m, 5H), 6.69 (br, 2H), 5.53 (d, J = 12.3
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Hz, 1H), 4.52 (m, 2H), 3.36 (s, 3H), 1.97 (m, 2H), 1.50-1.00 (m, 20H), 0.78 (t, J = 6.1 Hz,
3H); 13C NMR (75 MHz, MeOH-d4) δ 168.3, 155.1, 153.4, 151.7, 136.8, 136.4, 136.1,
133.6, 132.9 (× 2), 132.6, 132.3, 130.1 (× 2), 129.2 (× 2), 128.0, 127.1, 126.6, 124.0, 123.1,
121.4, 113.1, 110.9, 79.5, 46.1, 37.1, 33.0, 30.8, 30.7, 30.6, 30.5, 30.3, 29.5, 27.7, 23.7,
14.4; IR (film) ν max 3425, 3060, 2919, 2849, 1689, 1620, 1586, 1537, 1494, 1465, 1370,
1310, 1200, 1131, 799, 762, 697 cm−1; HRMS (ESI+) m/z 627.3523 (M+, C41H47N4S
requires 627.3521).
2-(3-Chloro-4-nitrophenyl)benzooxazole (82)
To a slurry of 3-chloro-4-nitro-benzoic acid (80, 1.0 g, 5.0 mmol) in DMF (15 mL) was
added HATU (1.9 g, 5.0 mmol) and DIEA (1.7 mL, 10 mmol). The reaction was stirred at
22 °C for 5 min prior to addition of 2-aminophenol (81, 550 mg, 5.0 mmol). The reaction
was stirred at 22 °C for 4 h followed by addition of saturated aqueous NaCl (150 mL). The
aqueous phase was extracted with diethyl ether (100 mL × 3). The organic phases were
combined and washed with saturated aqueous NaCl (100 mL), dried over anhydrous
Na2SO4, and concentrated in vacuo. To the slurry of resulting residue in xylene (30 mL) was
added p-toluenesulfonic acid (3.8 g, 20 mmol). The reaction was refluxed for 1 h, cooled,
and poured into aqueous NaOH (1.0 M, 100 mL). The aqueous phase was extracted with
diethyl ether (100 mL × 3). The organic phases were combined and washed with saturated
aqueous NaCl (100 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. Flash
column chromatography (hexane/ethyl acetate, 10:1) afforded the product (1.02 g, 71%) as a
off white solid; mp 162–164 °C; Rf = 0.58 (hexane/ethyl acetate, 3:1); 1H NMR (400 MHz,
CDCl3) δ 8.40 (d, J = 1.7 Hz, 1H), 8.23 (dd, J1 = 1.7 Hz, J2 = 8.5 Hz, 2H), 7.99 (d, J = 8.5
Hz, 1H), 7.79 (m, 1H), 7.61 (m, 1H), 7.41 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 159.4,
151.0, 149.0, 141.7, 131.8, 130.6, 128.0, 126.6, 126.2 (× 2), 125.4, 120.7, 111.0; IR (film) ν
max 3093, 1610, 1580, 1547, 1523, 1468, 1446, 1331, 1067, 762, 750 cm−1; HRMS (ESI+)
m/z 275.0238 (M+H+, C13H8N2O3Cl requires 275.0224).
(5-Benzooxazol-2-yl-2-nitrophenyl)ethylamine (85)
To a slurry of 82 (200 mg, 0.73 mmol) in DMSO (2 mL) was added ethylamine (83, 2.0 M
in THF, 4 mL). The reaction was stirred at 22 °C for 48 h. The reaction was poured into
aqueous HCl (1.0 M, 30 mL). The aqueous phase was extracted with diethyl ether (50 mL ×
3). The organic phases were combined and washed with saturated aqueous NaCl (50 mL),
dried over anhydrous Na2SO4, and concentrated in vacuo. Recrystallization of the crude
product from CH2Cl2/MeOH afforded the product (190 mg, 92%) as a orange solid; mp
168–170 °C; Rf = 0.55 (hexane/ethyl acetate, 3:1); 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J
= 8.9 Hz, 1H), 8.01 (br, 1H), 7.80 (m, 1H), 7.70 (d, J = 1.6 Hz, 1H), 7.59 (m, 1H), 7.46 (d,
J1 = 1.6 Hz, J2 = 8.9 Hz, 1H), 7.39 (m, 2H), 3.48 (m, 2H), 1.43 (t, J = 7.2 Hz, 3H); 13C
NMR (100 MHz, CDCl3) δ 161.2, 150.9, 145,3, 141,9, 133.6, 132.8, 127.7, 126.1, 125.1,
120.1, 113.6,112.8, 110.8, 38.0, 14.4; IR (film) ν max 3379, 2969, 2912, 2850, 1627, 1621,
1580, 1553, 1523, 1490, 1402, 1339, 1320, 1281, 1215, 1188, 1048, 743 cm−1; HRMS (ESI
+) m/z 284.1036 (M+H+, C15H14N3O3 requires 284.1035).
(5-Benzooxazol-2-yl-2-nitrophenyl)hexylamine (84)
Compound 82 (200 mg, 0.73 mmol) was added to hexylamine (38, 1.0 mL, 7.7 mmol) in
DMSO/THF (2 mL/2 mL) and stirred at 22 °C for 48 h. The reaction was worked up as
described for preparation of 85. Recrystallization of the crude product from CH2Cl2/MeOH
afforded the product (233 mg, 94%) as a orange solid; mp 134–135 °C; Rf = 0.68 (hexane/
ethyl acetate, 3:1); 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 8.9 Hz, 1H), 8.09 (br, 1H),
7.81 (m, 1H), 7.72 (d, J = 0.9 Hz, 1H), 7.60 (m, 1H), 7.46 (d, J1 = 0.9 Hz, J2 = 8.9 Hz, 1H),
7.40 (m, 2H), 3.42 (q, J = 5.2 Hz, 2H), 1.80 (m, 2H), 1.49 (m, 2H), 1.38 (m, 4H), 0.93 (t, J =
5.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 161.3, 150.9, 145.4, 141.9, 133.6, 132.8, 127.7,
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126.1, 125.1, 120.5, 113.5, 112.9, 110.8, 43.3, 31.5, 28.9, 26.7, 22.6, 14.0; IR (film) ν max
3368, 3077, 2950, 2924, 2857, 1630, 1622, 1582, 1556, 1523, 1491, 1470, 1451, 1407,
1318, 1284, 1260, 1244, 1211, 1191, 1180,1050, 760, 744 cm−1; HRMS (ESI+) m/z
340.1646 (M+H+, C19H22N3O3 requires 340.1661).
4-Benzooxazol-2-yl-N2-ethylbenzene-1,2-diamine (87)
Compound 85 (160 mg, 0.56 mmol) was treated with anhydrous hydrazine (0.1 mL, 3.2
mmol) and Pd/C (10%, 64 mg, 0.06 mmol) using the procedure described for preparation of
7. Recrystallization from CH2Cl2/hexane afforded the product (132 mg, 93%) as a light
yellow solid; mp 172–173 °C; Rf = 0.30 (hexane/ethyl acetate, 1:1); 1H NMR (400 MHz,
DMSO-d6) δ 7.65 (br, 2H), 7.36-7.18 (m, 4H), 6.66 (d, J = 7.6 Hz, 1H), 5.44 (s, 2H), 4.70
(br, 1H), 3.15 (m, 2H), 1.27 (m, 3H); 13C NMR (100 MHz, DMSO-d6) δ 164.7, 150.4,
142.7, 140.4, 135.8, 124.7, 124.4, 119.1, 118.3, 114.7, 113.3, 110.7, 108.0, 38.4, 14.8; IR
(film) ν max 3429, 3379, 3335, 3225, 2973, 2956, 2923, 2852, 1643, 1607, 1586, 1495,
1451, 1036, 1278, 1240, 1150, 1053, 856, 793, 759, 746 cm−1; HRMS (ESI+) m/z 254.1287
(M+H+, C15H16N3O requires 254.1293).
4-Benzooxazol-2-yl-N2-hexylbenzene-1,2-diamine (86)
Compound 84 (160 mg, 0.47 mmol) was treated with anhydrous hydrazine (0.1 mL, 3.2
mmol) and Pd/C (10%, 53 mg, 0.05 mmol) using the procedure described for preparation of
7. Recrystallization from CH2Cl2/hexane afforded the product (136 mg, 94%) as a light
yellow solid; mp 126–127 °C; Rf = 0.24 (hexane/ethyl acetate, 3:1); 1H NMR (400 MHz,
CDCl3) δ 7.72 (m, 2H), 7.62 (dd, J1 = 1.8 Hz, J2 = 8.0 Hz, 1H), 7.53 (m, 2H), 7.28 (m, 2H),
6.77 (d, J = 8.0 Hz, 1H), 3.6 (br, 3H), 3.20 (t, J = 7.2 Hz, 2H), 1.69 (m, 2H), 1.44 (m, 2H),
1.34 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 164.3,150.6, 142.4,
138.5, 137.5,124.2 (× 2), 119.3 (× 2), 118.7, 115.4, 110.8, 110.2, 44.4, 31.7, 29.7, 27.0,
22.6, 14.1; IR (film) ν max 3410, 3360, 3220, 2950, 2927, 2846, 1646, 1591, 1582, 1557,
1505, 1484, 1455, 1443, 1318, 1292, 1158, 955, 851, 797, 758, 743 cm−1; HRMS (ESI+) m/
z 310.1899 (M+H+, C19H24N3O requires 310.1919).
[(E)-2-(6-Benzooxazol-2-yl-1-ethyl-1H-benzoimidazol-2-yl)ethenyl]methyl phenylamine (17)
To a solution of 87 (51 mg, 0.2 mmol) and 10 (32 mg, 0.2 mmol) in ethanol (10 mL),
ZrOCl2·8H2O (32 mg, 0.1 mmol) was added. The reaction was stirred at 22 °C for 30 min.
The reaction was heated to 80 °C and refluxed for 5 min before the addition of MnO2 (86
mg, 1.0 mmol). After 10 min, the solution was cooled to 22 °C and filtered through a fritted
funnel. The MnO2 was washed with ethanol (10 mL). The combined filtrate was
concentrated in vacuo. Flash column chromatography (hexane/ethyl acetate, 3:1) afforded
the product (53 mg, 68%) as a yellow solid; mp 171–173 °C; Rf = 0.15 (hexane/ethyl
acetate, 1:1); 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 13.0 Hz, 1H), 8.12 (m, 2H),7.72
(m, 2H), 7.58 (m, 1H), 7.39-7.22 (m, 6H), 7.12 (t, J = 6.7 Hz, 1H), 5.38 (d, J = 13.0 Hz,
1H), 4.23 (q, J = 6.7 Hz, 2H), 3.38 (s, 3H), 1.47 (t, J = 6.7 Hz, 3H); 13C NMR (75 MHz,
CDCl3) δ 164.5, 156.0, 150.8, 146.8, 146.6, 143.5 (× 2), 142.5, 135.3, 129.4(× 2), 124.4,
124.3, 123.7, 121.9, 119.7 (× 2), 119.4, 119.0, 117.6, 110.3, 107.8, 85.9, 38.0, 36.5, 15.0; IR
(film) ν max 3379, 3060, 2978, 2934, 1628, 1594, 1558, 1491, 1453, 1410, 1347, 1326,
1291, 1242, 1128, 809, 747 cm−1; HRMS (ESI+) m/z 395.1849 (M+H+, C25H23N4O
requires 395.1872).
[(E)-2-(6-Benzooxazol-2-yl-1-hexyl-1H-benzoimidazol-2-yl)ethenyl]methylphenylamine (32)
To a solution of compound 86 (62 mg, 0.2 mmol) and 10 (32 mg, 0.2 mmol) in ethanol (10
mL), was added ZrOCl2·8H2O (32 mg, 0.1 mmol) to synthesize 32 using the procedure
described for preparation of 17. Flash column chromatography (hexane/ethyl acetate, 5:1)
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afforded the product (58 mg, 64%) as a yellow solid; mp 88–89 °C; Rf = 0.40 (hexane/ethyl
acetate, 1:1); 1H NMR (300 MHz, CDCl3) δ 8.35 (d, J = 13.1 Hz, 1H), 8.11-8.09 (m, 2H),
7.76 (m, 1H), 7.67 (dd, J1 = 0.9 Hz, J2 = 8.0 Hz, 1H), 7.56 (m, 1H), 7.38-7.30 (m, 4H),
7.23-7.21 (m, 2H), 7.10 (m, 1H), 5.37 (d, J = 13.1 Hz, 1H), 4.15 (t, J = 7.4 Hz, 2H), 3.37 (s,
3H), 1.85 (m, 2H), 1.35 (m, 6H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ
164.5, 156.3, 150.8, 146.6, 143.4, 142.5, 135.8, 129.4 (× 2), 124.4, 124.3, 123.7, 121.9,
119.7 (× 3), 119.4, 119.0, 117.6, 110.3, 108.0, 86.2, 43.3, 36.5, 31.5, 29.8, 26.6, 22.6, 14.0;
IR (film) ν max 3357, 3060, 2950, 2929, 2853, 1628, 1594, 1559, 1491, 1452, 1409, 1326,
1294, 1268, 1243, 1128, 1001, 823, 746, 695 cm−1; HRMS (ESI+) m/z 451.2472 (M+H+,
C29H31N4O requires 451.2498).
Biological assays
To construct the PIV5 strain used for antiviral assays, recombinant PIV5 encoding GFP
between the viral genes HN and L32 was modified by replacement of GFP in the PIV5
genome with renilla luciferase. Recombinant PIV5 expressing renilla luciferase (rPIV5-RL)
was confirmed by RT-PCR sequencing and functional assays. To examine whether
luciferase activity of infected cells reflects the rate of viral infection, a serial dilution (2 ✕)
of rPIV5-RL virus was used to infect HeLa cells grown on a 96-well plate. At 1 day post
infection (dpi), the cells were lysed and assayed for renilla luciferase activity (commercial
detection kit from Promega Inc., Madison, WI). As shown in Figure 3, at 0.06 to 8 MOI
(multiplicity of infectivity, corresponding to the number of infectious viruses per cell), the
luciferase activity directly correlated with the amount of virus applied, indicating that
rPIV5-RL can be used to quantitatively assess viral replication. To test the effects of
compounds on replication of rPIV5-RL, HeLa cells in 96-well plates were infected with 1
MOI of rPIV5-RL. The cells were incubated with compounds, collected at 1 day post
infection, and assayed for renilla luciferase activity.
To examine the toxicity of compounds to mammalian cells, cellular viability was quantified
after 24 h (HeLa cells) or 40 h (NHBE cells) with a firefly luciferase-based CellTiter-Glo
luminescent cell viability assay (Promega Inc., Madison, WI). Normal human bronchial
epithelial (NHBE) cells were cultured in an air-liquid interface system as previously
described.35 Briefly, NHBE cells (passage-2, 2×104 cells/cm2, Clonetics, San Diego, CA)
were cultured in Transwell-clear culture inserts (24.5 mm, 0.45 μm pore size; Costar,
Cambridge, MA) thin-coated with rat tail collagen, type I (Collaborative Res., Bedford,
MA). Cells were cultured submerged for the first 5 to 7 days. After this period, the apical
medium was removed to create the air-liquid interface, and cells were fed medium on their
basal surface only. For an additional 28 days, the apical surface of the cells was exposed to a
humidified 95% air/5% CO2 environment. NHBE cells were cultured for a total of 35 days.
Cultures of Mycobacterium fortuitum, a generous gift of Dr. Fred Quinn, were maintained at
37 °C in 7H9 broth supplemented with OADC and 0.05% glycerol. The assay in infected
HeLa cells was based on a related survival assay for M. tuberculosis.36 HeLa cells were
seeded in 24 well plates at 5 × 105 cells per well in EMEM containing 10% FBS (HeLa
medium) overnight in a CO2 (5%) incubator at 37 °C. M. fortuitum was washed with uptake
buffer (1 part Basal Uptake Buffer (4.5 mg/mL glucose, 5 mg/mL BSA, 0.1 mg/mL CaCl2,
0.1 mg/mL MgCl2, 1 mg/mL gelatin in PBS): 4 parts Wash Buffer (5% FBS in DMEM)).
After the wells had been washed to remove antibiotics, M. fortuitum in uptake buffer was
added to the wells containing HeLa cells (MOI = 5). After infection for 24 h, the medium
was removed, the wells were washed with warm DMEM, and this DMEM was replaced
with HeLa medium containing compounds 1 (0.5 μM), 29 (0.5 μM), 30 (0.5 μM), 31 (0.5
μM), TritonX-100 (1%), or DMSO (0.1%, vehicle control). After an additional 24 h, the
medium was removed and the cells were lysed, diluted, and plated for determination of
colony forming units (CFU) on 7H11 agar plates.
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Structure of AKT inhibitor IV (1).
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Structures of analogues 12 to 32. For 13 to 16 and 18 to 31, compounds were isolated as
ammonium iodides.
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Panel A: Design of recombinant PIV5 expressing renilla luciferase. The gene encoding
luciferase was inserted into the PIV5 genome between the HN and L genes. Panel B:
Validation of rPIV5-RL by luciferase assay of infected HeLa cells. The activity of the
highest dose of infection, 34 infectious viruses per cell, was set as 100%. Error bars
represent standard errors of the mean.
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Initial evaluation of compounds 1 and 12-32 against rPIV5-RL at one day post infection. All
compounds were tested at 1 μM. Compounds comparable in activity to 1 were further
examined at 0.5 μM (concentrations (μM) shown in brackets). Error bars represent standard
errors of the mean.
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Panels A-C: Dose-dependent effects of compounds 1 and 29-31 on renilla luciferase
expressed by rPIV5-RL in HeLa cells (Panel A), on viability of HeLa cells after 24 h (Panel
B), and on viability of NHBE cells after 40 h (Panel C). Viability of mammalian cells was
measured by quantification of cellular ATP with firefly luciferase. Panel D: Examination of
effects of compounds (0.5 μM) compared with Triton X-100 (1%) on replication of
intracellular M. fortuitum bacteria in HeLa cells. Data are in triplicate or larger numbers of
measurements. Standard errors of the mean are ≤ 20%.
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Synthesis of AKT inhibitor-IV (1).
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Synthesis of 13-16 and 18-31.
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Synthesis of 17 and 32.
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